NIR-II Fluorescence Imaging: A Comprehensive Guide for Advanced Lymphatic System Mapping and Diagnostic Applications

Abstract

This comprehensive review details the application of second near-infrared (NIR-II, 1000-1700 nm) fluorescence imaging for mapping and diagnosing the lymphatic system. Targeting researchers and drug development professionals, the article explores the fundamental advantages of NIR-II over traditional NIR-I, including superior tissue penetration, high spatial resolution, and exceptional signal-to-background ratios. It systematically covers key methodologies from contrast agent design to in vivo imaging protocols, addresses common experimental challenges and optimization strategies, and provides a critical comparison with existing imaging modalities. The article concludes by synthesizing the translational potential of NIR-II lymphatic imaging for advancing biomedical research and clinical diagnostics in oncology, immunology, and lymphatic disorders.

Beyond NIR-I: Understanding the Fundamental Advantages of NIR-II for Deep-Tissue Lymphatic Imaging

Within the context of advancing NIR-II fluorescence imaging for deep-tissue mapping, a precise understanding of lymphatic anatomy and physiology is paramount. This document details key imaging targets, their clinical relevance, and standardized protocols for their investigation using NIR-II agents, supporting thesis research on high-resolution in vivo lymphatic system diagnostics.

Key Anatomical Structures as NIR-II Imaging Targets

Lymphatic structures present distinct morphological and functional targets for contrast-enhanced imaging.

Table 1: Primary Lymphatic Imaging Targets and Clinical Correlates

Anatomical Target	Physiological Function	Clinical Relevance / Pathologic State	NIR-II Imaging Advantage
Initial Lymphatics (Capillaries)	Interstitial fluid uptake via endothelial buttons.	Lymphedema (impaired drainage), tumor cell entry.	High-resolution visualization of capillary uptake kinetics.
Collecting Lymphatic Vessels	Unidirectional lymph transport via valves & smooth muscle.	Primary lymphangiectasia, valve dysfunction.	Deep-tissue tracking of lymph flow velocity & valve competence.
Lymph Nodes (Cortical Sinuses)	Antigen & cell filtration, immune cell activation.	Metastasis (sentinel node), lymphoma, infection.	Quantification of tracer accumulation for nodal mapping & detection of architectural disruption.
Thoracic Duct & Right Lymphatic Duct	Return of lymph to venous circulation.	Chylothorax, duct injury, malformations.	Non-invasive mapping of ductal anatomy and site of leakage.

Physiological Pathways & Molecular Targets

Imaging functional physiology requires targeting specific cellular and molecular pathways.

Diagram 1: Key Lymphatic Signaling Pathways for Probe Design

Experimental Protocols for NIR-II Lymphatic Imaging

Protocol 3.1: Dynamic Lymphatic Uptake and Flow Imaging in a Murine Hindlimb Objective: Quantify the initial lymphatic uptake and propulsion kinetics of NIR-II contrast agents.

• Animal Preparation: Anesthetize mouse (e.g., C57BL/6) and place on a heated stage. Depilate the hindlimb.
• Tracer Administration: Prepare 10 µL of a 100 µM solution of a biocompatible NIR-II fluorophore (e.g., IRDye 800CW PEGylated nanoparticle). Using a 33-gauge insulin syringe, perform an intradermal injection into the dorsal footpad.
• NIR-II Image Acquisition: Position the animal under a NIR-II fluorescence imaging system (e.g., excitation: 808 nm, emission: 1000-1700 nm filter). Begin continuous image acquisition (1-5 fps) immediately post-injection for 10-15 minutes.
• Data Analysis: Use software to draw ROIs on initial capillaries, collecting vessels, and popliteal node. Generate time-intensity curves to calculate parameters: Time-to-first-detect (TFD), lymphatic velocity (pixel/s), and half-drainage time (T_1/2).

Protocol 3.2: Sentinel Lymph Node Mapping for Metastasis Assessment Objective: Identify and assess the drainage pattern and status of sentinel lymph nodes (SLNs).

• Tumor Model: Utilize a syngeneic or xenograft model (e.g., 4T1 breast carcinoma in BALB/c mouse).
• NIR-II Tracer Injection: At primary tumor diameter of 5-8 mm, inject 20 µL of a receptor-targeted NIR-II probe (e.g., anti-LYVE-1 Ab conjugate) peritumorally at 2-4 sites.
• Imaging Protocol: Acquire whole-body NIR-II images at 1 min, 5 min, 30 min, and 2 hrs post-injection. Maintain a standardized field of view and laser power.
• Ex Vivo Validation: Euthanize the animal at the terminal time point. Surgically excise the identified SLN and secondary nodes for ex vivo imaging. Process nodes for histology (H&E) to correlate NIR-II signal with metastatic burden.

Protocol 3.3: Quantitative Assessment of Lymphatic Vascular Leakiness in Lymphedema Objective: Evaluate lymphatic vessel integrity in a surgical tail lymphedema model.

• Disease Model: Generate a mouse tail lymphedema model by surgically ablating a 2-mm segment of the main lateral lymphatic vessel.
• Imaging Time Point: Perform imaging at postoperative day 7 (peak inflammatory phase).
• Tracer Administration: Inject 10 µL of a high molecular weight (≥70 kDa) NIR-I/II dye conjugate (e.g., ICG-HAS) intradermally 3 cm distal to the ablation site.
• Leakage Quantification: Acquire time-series images over 60 mins. Calculate the "leakage index" as the ratio of integrated fluorescence intensity in the peri-lymphatic tissue (ROI 5 pixels adjacent to the vessel) to the intensity within the vessel lumen at t=30min.

The Scientist's Toolkit: Key Research Reagents & Materials

Table 2: Essential Reagents for NIR-II Lymphatic Imaging Research

Item	Function / Role	Example / Specification
NIR-II Fluorophores	Provides contrast for deep-tissue, high-resolution imaging.	Organic dyes (CH-1055), Quantum Dots (Ag2S), Single-Walled Carbon Nanotubes (SWCNTs).
Lymphatic-Targeting Moieties	Directs contrast agents to specific molecular targets.	Anti-LYVE-1 antibodies, VEGF-C/D proteins, CCL21 chemokine.
Hydrodynamic Size Standards	Controls lymphatic uptake and transport based on particle size.	Dextran conjugates (3-5 nm), PEGylated nanoparticles (10-50 nm), Albumin-bound dyes (≈7 nm).
Animal Disease Models	Provides pathophysiological context for imaging studies.	K14-VEGF-C transgenic (lymphangiogenesis), Prox1 haploinsufficient (lymphedema), Tumor implant (metastasis).
Intradermal Injection Syringes	Ensures precise delivery of tracer to the interstitial/lymphatic compartment.	33-gauge, 0.5-inch needle, 0.3 mL insulin syringes.
NIR-II Imaging System	Captures and quantifies fluorescence emission >1000 nm.	System with 808 nm or 980 nm laser, InGaAs camera, 1000-1700 nm bandpass filters.

Diagram 2: NIR-II Lymphatic Imaging Experiment Workflow

Intravital imaging has undergone a paradigm shift with the transition from the first near-infrared window (NIR-I, 700–900 nm) to the second near-infrared window (NIR-II, 1000–1700 nm). This evolution is central to advancing research in lymphatic system mapping and diagnosis, a key thesis focus. NIR-II imaging offers significantly reduced photon scattering and autofluorescence, enabling deeper tissue penetration, higher spatial resolution, and improved signal-to-background ratios (SBR) for visualizing dynamic lymphatic structures and functions in vivo.

Quantitative Comparison: NIR-I vs. NIR-II

Table 1: Performance Metrics of NIR-I vs. NIR-II Imaging Windows

Parameter	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)	Improvement Factor
Tissue Penetration Depth	1-2 mm	3-5 mm	~2-3x
Spatial Resolution	~20-40 μm	~10-25 μm	~1.5-2x
Temporal Resolution	Moderate (sec-min)	High (sub-sec to sec)	Enhanced
Signal-to-Background Ratio (SBR)	Low-Moderate (often < 10)	High (often > 20)	>2-5x
Autofluorescence	High	Negligible	Drastically Reduced
Maximum Allowable Exposure Power (Skin)	~0.33 W/cm²	~1.0 W/cm²	~3x

Table 2: Common Fluorophores for Lymphatic Imaging

Fluorophore Type	Emission Window	Example Agent	Quantum Yield	Key Application in Lymphatics
Organic Dyes	NIR-I	ICG (Indocyanine Green)	~0.03-0.1	Sentinel lymph node mapping
Quantum Dots	NIR-II	Ag₂S QDs	~0.3-0.5	Deep-tissue lymphatic vessel tracking
Single-Walled Carbon Nanotubes (SWCNTs)	NIR-II	(6,5)-SWCNT	~0.01-0.1	Long-term imaging of lymph flow
Lanthanide-Doped Nanoparticles	NIR-II	NaYF₄:Nd³⁺	~0.3	High-contrast vascular imaging
Donor-Acceptor-Dye (D-A-D) Polymers	NIR-II	pDA	~0.05	Real-time lymphangiography

Core Experimental Protocols

Protocol 1: NIR-II Intravital Imaging of Murine Lymphatic Drainage

Objective: To visualize real-time lymphatic drainage and valve function in a mouse model using NIR-II fluorescent probes.

Materials: See "The Scientist's Toolkit" below.

Procedure:

• Animal Preparation: Anesthetize a transgenic or wild-type mouse (e.g., C57BL/6) using an approved protocol (e.g., 2% isoflurane). Secure the animal on a heated stage (37°C).
• Probe Administration: Prepare a 100 µM solution of an NIR-II fluorophore (e.g., CH-4T or Ag₂S QDs) in sterile PBS. Inject 20 µL intradermally into the paw pad or ear pinna using a 31-gauge insulin syringe.
• Microscope Setup: Use a commercially available or custom-built NIR-II imaging system. Key settings:
  • Laser Excitation: 808 nm laser for 980 nm+ emission probes; 980 nm laser for 1500 nm+ emission.
  • Detector: Two-dimensional InGaAs array camera cooled to -80°C.
  • Filters: Long-pass filter (cut-on at 1000 nm or 1500 nm) placed before the detector.
  • Objective: 10X long-working-distance air objective (NA 0.3).
• Image Acquisition:
  • Begin imaging immediately post-injection.
  • Acquire time-series images at 2-5 frames per second for 5-10 minutes to capture dynamic drainage.
  • For high-resolution structural imaging, switch to a higher NA objective and acquire z-stacks.
• Data Analysis: Use software (e.g., ImageJ, MATLAB) to quantify:
  • Lymphatic Flow Velocity: Track discrete fluorescent spots between frames.
  • Vessel Diameter: Measure full-width at half-maximum (FWHM) of intensity profiles.
  • Signal-to-Background Ratio (SBR): Calculate as (Mean Signal Intensity - Mean Background Intensity) / Standard Deviation of Background.

Protocol 2: Comparative NIR-I/NIR-II Lymph Node Mapping

Objective: To compare the efficacy of ICG (NIR-I) and an NIR-II probe for sentinel lymph node (SLN) mapping.

Procedure:

• Dual-Probe Preparation: Prepare ICG (10 µM) and an NIR-II probe (e.g., IR-E1050, 10 µM) in separate vials.
• Animal Model: Use a subcutaneous tumor model (e.g., 4T1 breast cancer in mouse flank).
• Injection: Co-inject 10 µL of each probe mixture intratumorally at adjacent sites.
• Dual-Channel Imaging: Employ a spectral unmixing system or sequential imaging with:
  • NIR-I Channel: 785 nm excitation, 810/40 nm emission filter.
  • NIR-II Channel: 980 nm excitation, 1300 nm long-pass filter.
• Analysis: Determine the time-to-detection, SBR of the identified SLN, and the number of secondary lymph nodes resolved in each channel.

Diagrams

Title: NIR-I vs NIR-II Experimental Workflow for Lymphatic Research

Title: Evolution from NIR-I to NIR-II: Drivers and Outcomes

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for NIR-II Lymphatic Imaging Experiments

Item	Function & Rationale	Example Product/Catalog
NIR-II Fluorescent Probe	High-quantum-yield emitter for in vivo labeling. Essential for generating signal in the NIR-II window.	CH-4T dye; Ag₂S Quantum Dots (QDs)
ICG (Indocyanine Green)	Standard NIR-I fluorophore for comparative validation studies.	Sigma-Aldrich, 12633
InGaAs NIR-II Camera	Sensitive detector for 900-1700 nm light. Critical for capturing weak NIR-II signals.	Princeton Instruments NIRvana; Hamamatsu C12741-03
808 nm or 980 nm Laser	Excitation source for NIR-II probes. Must match probe absorption peak.	CNI Laser, MDL-III-808/980
Long-Pass Emission Filter (>1000 nm)	Blocks excitation and NIR-I light, ensuring only NIR-II signal is detected.	Thorlabs FELH1000
Animal Model (Mouse)	In vivo system for studying lymphatic physiology and disease.	C57BL/6; Prox1-GFP transgenic mice
Image Analysis Software	For quantifying flow dynamics, vessel morphology, and signal intensity.	ImageJ with NIR-II plugins; MATLAB
Micro-injection Syringe	Precise intradermal or interstitial delivery of fluorescent probes.	Hamilton 7000 Series, 33-gauge needle

Within the context of NIR-II (1000-1700 nm) imaging for lymphatic system mapping and diagnosis, the selection of contrast agent platform is critical. Organic dyes, quantum dots (QDs), and single-walled carbon nanotubes (SWCNTs) constitute the three primary platforms, each offering distinct optical and physicochemical properties that influence lymphatic targeting efficiency, biodistribution, and translational potential.

Platform Characteristics & Quantitative Comparison

Table 1: Core Characteristics of NIR-II Lymphatic Contrast Agent Platforms

Property	Organic Dyes (e.g., IRDye 800CW, CH-4T)	Quantum Dots (e.g., Ag2S, PbS/CdS)	Single-Walled Carbon Nanotubes (SWCNTs)
Core Size (nm)	~1-2 (hydrodynamic radius)	3-10 nm (core diameter)	Length: 200-500 nm; Diameter: ~1 nm
Peak Emission (nm)	800-1000 (NIR-I) / 1000-1200 (NIR-II)	Tunable, typically 1000-1600 nm	1000-1600 nm (based on chirality)
Quantum Yield	Low to Moderate (0.5-5% in NIR-II)	High (10-25% in NIR-II)	Low (~1% in NIR-II)
Extinction Coefficient (M⁻¹cm⁻¹)	~10⁵	Very High (10⁵-10⁶)	Very High (10⁵-10⁶ per cm⁻¹ per atom)
Photostability	Low to Moderate	Excellent	Exceptional
Typical Lymphatic Targeting Mode	Passive drainage from interstitial injection	Passive drainage; potential for active targeting via surface conjugation	Passive drainage; prolonged residency
Primary Clearance Route	Renal & Hepatobiliary	Size-dependent: Renal (small) or RES (larger)	Slow, primarily RES sequestration
Key Advantage	Clinical translation, rapid clearance	Brightness, tunability, multiplexing	Deep tissue penetration, photostability
Key Limitation	Lower brightness in NIR-II, photobleaching	Potential heavy metal toxicity, size	Potential persistence, complex chemistry

Table 2: In Vivo Performance Metrics in Murine Lymphatic Models

Metric	Organic Dyes	Quantum Dots	SWCNTs
Signal-to-Background Ratio (Popliteal LN)	~5-15 (at 5 min post-injection)	~20-50 (at 5 min post-injection)	~10-30 (at 5 min post-injection)
Time to Peak LN Signal (min)	2-10	3-10	5-15
LN Retention Half-life	< 60 min	1-4 hours	> 24 hours
Optimal Imaging Depth (mm)	3-5	5-10	>10
Common Functionalization	PEGylation, biomolecule conjugation	PEGylation, peptide, antibody coating	PEGylation (PL-PEG), phospholipid coating

Data synthesized from recent literature (2022-2024). *Estimated in tissue-mimicking phantoms.

Detailed Experimental Protocols

Protocol 1: Intradermal Injection and NIR-II Imaging of Lymphatic Drainage in Mice

Objective: To evaluate the dynamic drainage and nodal accumulation of a contrast agent. Materials:

• Anesthetized mouse (e.g., C57BL/6)
• NIR-II contrast agent solution (in sterile PBS, 50-100 µM)
• NIR-II fluorescence imaging system (e.g., InGaAs camera with 808 nm or 980 nm laser)
• 31G insulin syringe
• Heating pad for animal warmth.

Procedure:

• Animal Preparation: Anesthetize the mouse using isoflurane (2-3% in O₂). Depilate the hind paw and lower leg. Secure the mouse in a supine position on a warming stage.
• Agent Administration: Intradermally inject 10 µL of contrast agent solution into the distal footpad of the hind limb using a 31G insulin syringe. Ensure a bleb forms, confirming intradermal placement.
• Image Acquisition: a. Position the imaging region of interest (hind limb & popliteal fossa) under the camera. b. Begin continuous imaging immediately post-injection (frame rate: 1-5 frames/sec for first 2 min, then 1 frame/min for 30 min). c. Use appropriate long-pass filters (e.g., LP 1000 nm, LP 1200 nm, LP 1500 nm) to capture NIR-II emission. d. Maintain anesthesia and body temperature throughout.
• Data Analysis: Use region-of-interest (ROI) analysis to quantify signal intensity in the draining popliteal lymph node versus adjacent background tissue over time. Calculate metrics: time-to-peak, signal-to-background ratio (SBR), and retention kinetics.

Protocol 2: Surface Functionalization of SWCNTs for Lymphatic Targeting

Objective: To coat SWCNTs with phospholipid-polyethylene glycol (PL-PEG) for stable, biocompatible lymphatic imaging. Materials:

• Raw HiPco SWCNTs (e.g., from NanoIntegris)
• Phospholipid-PEG (e.g., DSPE-PEG2000)
• Sodium cholate (1-2% w/v in PBS)
• Probe sonicator with tip
• Ultracentrifuge
• 100 kDa molecular weight cut-off (MWCO) centrifugal filters.

Procedure:

• Initial Dispersion: Weigh 1 mg of raw SWCNTs and add to 10 mL of 1% sodium cholate in PBS. Sonicate using a probe sonicator on ice (1-2 hr, amplitude 40%, pulse 5s on/5s off) until a homogeneous black dispersion is achieved.
• Centrifugation: Centrifuge the dispersion at 100,000 x g for 1 hour at 4°C to pellet large aggregates and catalyst particles. Collect the supernatant containing individually dispersed SWCNTs.
• PEGylation: Add DSPE-PEG2000 to the supernatant at a 10:1 weight ratio (PEG:SWCNTs). Vortex thoroughly. Incubate the mixture at 4°C for 12-16 hours with gentle stirring.
• Purification: Transfer the mixture to a 100 kDa MWCO centrifugal filter. Centrifuge at 5,000 x g for 15 min. Discard the flow-through containing free sodium cholate and excess PEG. Resuspend the retentate in sterile PBS. Repeat this wash step 3-5 times.
• Characterization: Measure absorbance spectrum to confirm dispersion. Determine concentration via absorbance at 808 nm (ε ~ 7.9 x 10⁶ M⁻¹cm⁻¹ per cm⁻¹ per atom). Validate coating via zeta potential shift towards neutrality and dynamic light scattering (DLS) for hydrodynamic size (~50-150 nm).

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Lymphatic Imaging Research

Item	Function & Key Consideration
IRDye 800CW PEG (Li-Cor)	Common clinical-grade NIR-I/NIR-II dye; benchmark for lymphatic drainage studies.
CH-4T Dye (Kairos Chem)	High-performance NIR-II organic dye; brighter than IRDye 800CW in NIR-II window.
Ag2S Quantum Dots (e.g., NN-Labs)	Heavy-metal-free NIR-II QDs; good compromise between brightness and biocompatibility.
PbS/CdS Core/Shell QDs (Ocean NanoTech)	High quantum yield NIR-II probes; require careful toxicity assessment.
HiPco SWCNTs (NanoIntegris)	Source of high-quality, semiconducting nanotubes for NIR-II imaging.
DSPE-mPEG (2000) (Nanocs)	Standard PEGylation reagent for creating stealth coatings on nanoparticles.
Phospholipid-PEG-NH₂ / -COOH (Avanti)	For introducing functional groups to nanoparticles for subsequent bioconjugation.
InGaAs NIR Camera (e.g., Sensors Unlimited/Xenics)	Essential detector for NIR-II light; cooled models reduce dark noise.
808 nm or 980 nm Laser Diode	Common excitation sources for NIR-II agents; 980 nm reduces tissue autofluorescence.
Long-Pass Optical Filters (e.g., Thorlabs, Semrock)	Critical for isolating NIR-II emission (e.g., FELH1000, FELH1200).

Visualized Workflows and Pathways

Title: Lymphatic Imaging Workflow with Three Agent Platforms

Title: Agent Design Logic for Lymphatic Targeting

From Lab to Pre-Clinical Models: Protocols for NIR-II Lymphatic Mapping and Functional Diagnosis

Within the broader thesis on NIR-II imaging for lymphatic system mapping and diagnosis, the choice of administration route for contrast agents is a critical determinant of imaging success. Intradermal (ID), subcutaneous (SC), and intravenous (IV) injections offer distinct pharmacokinetic profiles, directly influencing lymphatic uptake, signal intensity, and diagnostic interpretation. These strategies enable targeted investigation of lymphatic architecture, vessel function, and node status, which are essential for research in oncology, immunology, and drug delivery systems.

Quantitative Comparison of Injection Strategies

Table 1: Comparative Pharmacokinetic and Imaging Parameters for NIR-II Contrast Agent Administration

Parameter	Intradermal (ID)	Subcutaneous (SC)	Intravenous (IV)
Primary Target	Initial lymphatic capillaries	Lymphatic capillaries & interstitial space	Blood vasculature; lymph nodes via extravasation
Typical Injection Volume	10-100 µL	100-500 µL	100-200 µL (bolus)
Injection Depth	0.5-1.5 mm (blister formation)	3-10 mm (tent-like lift)	Direct venous access
Onset of Lymphatic Uptake	10-30 seconds	1-5 minutes	15-60 minutes (passive drainage)
Peak NIR-II Signal in Lymph Nodes	5-15 minutes	30-90 minutes	60-180 minutes
Key Advantage	Rapid, high-contrast mapping of lymphatic capillaries	Sustained delivery for functional flow studies	Systemic delivery for surveying deep nodes
Primary Research Application	Sentinel lymph node mapping, capillary integrity	Lymphatic drainage kinetics, interstitial transport	Metastatic survey, vascular-lymphatic interface

Detailed Experimental Protocols

Protocol 3.1: Intradermal Injection for Sentinel Lymph Node Mapping (NIR-II)

Objective: To deliver NIR-II fluorescent contrast agent (e.g., IRDye 800CW, quantum dots, or carbon nanotubes) for high-spatial-resolution mapping of dermal lymphatic capillaries and sentinel lymph nodes.

Materials:

• NIR-II fluorescent contrast agent (e.g., 10 µM solution in sterile PBS)
• Insulin syringe with a 29-31 gauge, short-bevelled needle
• Animal model (e.g., mouse, dorsal side shaved)
• NIR-II fluorescence imaging system
• Isoflurane anesthesia setup
• Heating pad (37°C)

Procedure:

• Anesthetize the animal and position on a heating pad to maintain lymphatic flow.
• Load a 50 µL volume of contrast agent into the insulin syringe, ensuring no air bubbles.
• Stretch the skin taut at the injection site (e.g., distal paw or tail base).
• Insert the needle, bevel up, at a 10-15° angle, just until the bevel is visible within the skin.
• Slowly inject 10-20 µL. A successful intradermal injection will produce a visible, transient "bleb" or blister (approximately 2-3 mm in diameter). Resistance should be felt.
• Withdraw the needle without applying pressure to the site.
• Immediately initiate dynamic NIR-II imaging (e.g., 1 frame/sec for 5 mins) to capture agent entry into initial lymphatics.
• Continue periodic imaging (e.g., every 5 mins) to track progression to sentinel node(s).

Protocol 3.2: Subcutaneous Injection for Lymphatic Drainage Kinetics

Objective: To administer contrast agent into the hypodermis for studying drainage rates and functional lymphatic vessel uptake over an extended period.

Procedure:

• Prepare animal and agent as in Protocol 3.1.
• Pinch a fold of skin at the injection site (e.g., dorsal flank) to elevate the subcutaneous space.
• Insert a 27-30 gauge needle at a 45° angle into the base of the skin fold. The needle should move freely with minimal resistance.
• Inject 100-200 µL of contrast agent. A broad, diffuse elevation (tent) should form without a superficial bleb.
• Release the skin fold and withdraw the needle.
• Begin time-lapse NIR-II imaging. Capture images every 30 seconds for the first 10 minutes, then every 5 minutes for up to 2 hours.
• Quantify signal intensity over time in proximal collecting vessels and lymph nodes to calculate drainage kinetics.

Protocol 3.3: Intravenous Injection for Systemic Lymph Node Survey

Objective: To achieve systemic circulation of a lymphotropic NIR-II agent for surveying multiple or deep lymph nodes, particularly for metastatic involvement studies.

Procedure:

• Place a tail vein catheter or establish retro-orbital venous access in the anesthetized animal.
• Prepare a bolus of 100 µL of contrast agent (higher concentration may be required for sufficient lymph node accumulation).
• Administer the bolus steadily over 10-15 seconds via the venous route.
• Flush with 50 µL of sterile saline.
• Start whole-body NIR-II imaging at 1-minute intervals for the first 15 minutes to capture vascular clearance.
• Continue imaging at 10-minute intervals from 30 minutes to 3 hours post-injection, focusing on lymph node basins.
• Signal in lymph nodes will increase gradually as the agent extravasates from blood vessels and is drained by interstitial flow.

Diagrams

Title: Contrast Agent Injection Strategy Decision Pathway

Title: Pharmacokinetic Pathways by Injection Route

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II Lymphatic Imaging Studies

Item	Function & Rationale
NIR-II Fluorophores(e.g., IRDye 800CW, PbS/CdS Quantum Dots, Single-Wall Carbon Nanotubes, Organic Dyes like CH-4T)	Emit fluorescence in the 1000-1700 nm range, enabling deep-tissue penetration, reduced scattering, and minimal autofluorescence for high-contrast lymphatic imaging.
Sterile, Isotonic Buffer(e.g., 1X PBS, pH 7.4)	Standard vehicle for contrast agent dilution and injection. Maintains osmotic balance to minimize tissue irritation and flow artifacts.
Ultra-Fine Insulin Syringes(29-31G, 0.3-0.5 mL)	Precision delivery of microliter volumes for ID and SC injections. Short-bevelled needles facilitate accurate depth control.
Tail Vein Catheter Set(27-30G, with restrainer)	Enables reliable, repeated IV bolus administration in rodent models, crucial for kinetic studies and agent distribution.
Animal Heating Platform	Maintains core body temperature at 37°C under anesthesia, which is critical for preserving normal lymphatic fluid flow and pumping function.
NIR-II Fluorescence Imaging System	Comprises a laser/excitation source (e.g., 808 nm), InGaAs or SWIR camera detectors, and spectral filters. Essential for capturing real-time lymphatic trafficking.
Image Analysis Software(e.g., ImageJ with NIR-II plugins, commercial SWIR analysis suites)	Quantifies signal intensity, flow velocity, and node accumulation metrics from time-series NIR-II image data.

This document provides detailed application notes and protocols for near-infrared window II (NIR-II, 1000-1700 nm) imaging, specifically tailored for lymphatic system mapping and diagnostic research. The enhanced penetration and reduced scattering in the NIR-II region enable high-resolution, deep-tissue visualization of lymphatic architecture and function, which is critical for studying metastasis, drug delivery, and lymphedema.

Core Imaging System Configuration

Camera Selection and Specifications

NIR-II imaging requires cameras with high quantum efficiency in the 1000-1700 nm range. InGaAs (Indium Gallium Arsenide) cameras are standard.

Table 1: Quantitative Comparison of Common NIR-II Camera Types

Camera Type	Spectral Range (nm)	Quantum Efficiency @ 1500 nm	Cooling Method	Pixel Size (µm)	Typical Frame Rate (fps)	Relative Cost
Standard InGaAs	900-1700	~80%	Thermoelectric (-80°C)	25	100	$$$$
Extended InGaAs	1000-2200	~70% @ 1500 nm	Deep Thermoelectric	25	50	$$$$$
2D gated InGaAs	900-1700	~75%	Liquid Nitrogen	20	1 (gated)	$$$$$$

Optimal excitation depends on the fluorophore used (e.g., IRDye 800CW, CH-4T, Ag2S quantum dots). Common lasers are used for stability and coherence.

Table 2: Laser Sources for NIR-II Fluorophore Excitation

Fluorophore Type	Excitation Max (nm)	Recommended Laser (nm)	Power Range (mW)	Modulation Capability
Organic Dyes (e.g., CH-4T)	~790 nm	785 nm diode laser	50-200	CW or pulsed
Quantum Dots (e.g., Ag2S)	~808 nm	808 nm diode laser	100-500	CW
Single-Wall Carbon Nanotubes	808 nm or 980 nm	808 nm or 980 nm laser	200-1000	Pulsed preferred

Filter Sets

Precise filter selection is critical to isolate NIR-II emission from excitation and autofluorescence.

Table 3: Essential Filter Specifications for NIR-II Lymphatic Imaging

Filter Purpose	Type	Cut-on/Cut-off Wavelength (nm)	Optical Density (OD)	Placement
Excitation Clean-up	Bandpass	e.g., 785/10 (for 785 nm laser)	>OD6	Before sample
Dichroic Mirror	Longpass	LP 800 or LP 900	N/A	After sample, before cam
Emission Filter	Longpass	LP 1000, LP 1200, or LP 1500	>OD4	Before camera

Animal Preparation Protocol for Lymphatic Imaging

Protocol 3.1: Subcutaneous Injection for Dermal Lymphatic Mapping

Objective: To visualize initial lymphatic capillaries and draining vessels in a mouse model. Materials:

• Anesthetized mouse (e.g., C57BL/6, 8-12 weeks old)
• NIR-II fluorophore (e.g., 100 µL of 10 µM IRDye 800CW PEG in PBS)
• Insulin syringe (29G)
• Hair removal cream
• Heating pad Procedure:

• Anesthetize the mouse using isoflurane (3% induction, 1.5-2% maintenance).
• Apply hair removal cream to the region of interest (e.g., footpad, tail base, ear). Wait 1 minute, then wipe clean with wet gauze.
• Place the animal on a 37°C heating pad on the imaging stage to maintain body temperature and vasodilation.
• Using an insulin syringe, inject 10-20 µL of the fluorophore solution intradermally or subcutaneously at the target site.
• Immediately initiate time-lapse imaging (1 frame/sec for 5-10 minutes) to capture fluorophore uptake and transport through initial lymphatics.

Protocol 3.2: Intravenous Injection for Systemic Lymph Node Mapping

Objective: To visualize major draining lymph nodes (e.g., popliteal, axillary, cervical) via passive accumulation. Materials:

• Anesthetized mouse
• NIR-II fluorophore (e.g., 200 µL of 100 µM Ag2S QDs in saline)
• Catheter (27G) placed in the tail vein
• Surgical tools for dissection (for terminal validation) Procedure:

• Anesthetize and prepare the mouse as in Protocol 3.1, Step 1-3.
• Secure a tail vein catheter.
• Inject the fluorophore solution via the catheter. Flush with 50 µL of saline.
• Allow circulation for 5-15 minutes. Acquire static images of lymph node basins (e.g., axillary, inguinal regions) using appropriate NIR-II filters (e.g., LP 1500 nm).
• For validation, euthanize the animal, dissect the suspected lymph nodes, and image ex vivo.

Protocol 3.3: Surgical Exposure for Deep Lymphatic Duct Imaging

Objective: To image the thoracic duct or mesenteric lymphatics requiring laparotomy. Materials:

• Anesthetized mouse, fixed in supine position.
• Sterile surgical tools (scissors, forceps, retractors).
• Sterile saline and gauze.
• NIR-II fluorophore for intravenous injection.
• Physiological monitoring equipment (e.g., ECG, temperature probe). Procedure:

• Perform a midline laparotomy under deep anesthesia.
• Gently exteriorize the intestines and cover with saline-moistened gauze.
• Locate the mesenteric lymphatics or the thoracic duct.
• Administer the NIR-II fluorophore intravenously.
• Position the imaging arm over the exposed area. Use sterile drapes to protect the optics. Acquire video-rate imaging to visualize duct contraction and flow.

The Scientist's Toolkit: Key Research Reagent Solutions

Table 4: Essential Materials for NIR-II Lymphatic Imaging Research

Item	Function/Explanation	Example Product/Catalog #
NIR-IIb Fluorophore (CH-4T)	Organic dye with emission >1000 nm for high-contrast imaging.	Lumiprobe (or equivalent), CAS 2235373-80-7
PEGylated IRDye 800CW	Commercially available, bright NIR-I/NIR-II dye for labeling.	LI-COR Biosciences, IRDye 800CW PEG
Ag2S Quantum Dots	Bright, photostable NIR-II emitter for deep-tissue mapping.	NN-Labs (or equivalent), SS-820
Matrigel Matrix	For creating lymphangiogenesis assays or tumor models.	Corning, 356231
Lymphatic Markers (Antibodies)	For histology validation (e.g., LYVE-1, Podoplanin).	R&D Systems, AF2125 (anti-mouse LYVE-1)
Isoflurane Anesthesia System	Precise and safe inhalation anesthesia for in vivo imaging.	VetEquip or SurgiVet systems
Animal Temperature Controller	Maintains core body temperature during prolonged imaging.	Harvard Apparatus, Homeothermic Monitor
Immobilization Stage	Customizable stage for reproducible animal positioning.	Thorlabs, MBT616D/M

Workflow and Signaling Visualization

Diagram Title: NIR-II Lymphatic Imaging Workflow

Diagram Title: NIR-II Probe Trafficking Through Lymphatic System

Real-Time Lymphatic Vessel Mapping and Sentinel Lymph Node Biopsy Guidance

Sentinel lymph node biopsy (SLNB) is a critical oncologic procedure for staging cancers, including melanoma and breast carcinoma. The current standard employs blue dyes and Technetium-99m-based radiocolloids, which have limitations in real-time visualization depth, resolution, and radiation exposure. Near-infrared window II (NIR-II, 1000-1700 nm) fluorescence imaging presents a transformative approach, offering superior spatial resolution, millimeter-to-centimeter depth penetration, and real-time guidance. This application note details protocols for NIR-II-based lymphatic mapping, framed within ongoing thesis research on advanced lymphatic system diagnostics.

Table 1: Comparison of Lymphatic Tracers for SLNB Guidance

Tracer Type	Emission λ (nm)	Peak SNR in Tissue	Resolution at 5 mm Depth	Clearance Time (Primary Lymphatic)	Clinical Status
ICG (NIR-I)	~820	15 ± 3	~0.5 mm	5-10 min	Approved, Widely Used
IRDye 800CW	~800	18 ± 4	~0.5 mm	8-12 min	Investigational
Ag2S QDs (NIR-II)	~1200	45 ± 8	~0.2 mm	15-25 min	Pre-clinical
CH1055-PEG (NIR-II)	~1055	52 ± 10	~0.25 mm	10-20 min	Pre-clinical
SWCNTs	~1300-1400	40 ± 6	~0.3 mm	>60 min	Pre-clinical

Table 2: Performance Metrics of NIR-II vs. Standard SLNB Techniques in Pre-clinical Models

Metric	Radio-guidance (γ-probe)	Blue Dye (Visual)	NIR-I Fluorescence	NIR-II Fluorescence
Real-Time Video Rate Imaging	No	Yes	Yes	Yes
Spatial Resolution	>10 mm	1-2 mm	0.5-1 mm	0.2-0.3 mm
Signal-to-Background Ratio (SBR)	N/A	2-3	8-12	20-50
Penetration Depth for Mapping	Deep	Superficial	3-5 mm	8-15 mm
Quantifiable Drainage Kinetics	No	No	Semi-quantitative	Fully Quantitative

Experimental Protocols

Protocol 3.1: Synthesis and Characterization of NIR-II Fluorophore (CH1055-PEG)

Objective: Prepare a water-soluble, biocompatible NIR-II fluorophore for lymphatic mapping. Materials: CH1055 dye (commercially available), Methoxy-PEG-NH₂ (5 kDa), DMSO (anhydrous), NHS, EDC, PD-10 desalting column, PBS (pH 7.4).

Procedure:

• Dissolve 5 mg CH1055-COOH in 1 mL anhydrous DMSO.
• Add 10 molar equivalents each of NHS and EDC. React for 30 minutes at room temperature with stirring to activate carboxyl groups.
• Add 1.2 molar equivalents of mPEG-NH₂ (5 kDa) dropwise. React for 12 hours at room temperature under inert atmosphere.
• Terminate the reaction by adding 100 µL of 1M hydroxylamine.
• Purify the conjugate (CH1055-PEG) using a PD-10 column equilibrated with PBS. Collect the first colored fraction.
• Characterize using UV-Vis-NIR spectroscopy (confirm absorbance peak ~750 nm) and fluorescence spectrometry (emission peak ~1055 nm). Determine concentration and degree of labeling.

Protocol 3.2: In Vivo Real-Time Lymphatic Mapping and SLNB in Murine Model

Objective: Visualize lymphatic drainage and identify sentinel lymph nodes in real-time. Animal Model: Female C57BL/6 mice (8-10 weeks). Imaging System: NIR-II fluorescence microscope equipped with a 1064 nm continuous-wave laser, InGaAs camera, and 1300 nm long-pass filter.

Procedure:

• Anesthesia: Anesthetize mouse using 2% isoflurane in oxygen. Depilate the hind paw.
• Tracer Injection: Subcutaneously inject 50 µL of 100 µM CH1055-PEG solution into the dorsal surface of the hind paw using a 31-gauge insulin syringe.
• Real-Time Imaging:
  • Immediately place the animal under the NIR-II imaging system.
  • Acquire time-lapse images (1 frame/sec for 5 min, then 1 frame/min for 30 min).
  • Track the initial capillary lymphatic uptake, collecting vessel propulsion, and arrival at the popliteal (sentinel) and subsequent iliac lymph nodes.
• SLNB Guidance:
  • Using the real-time NIR-II video feed as a guide, make a small incision over the fluorescent popliteal node.
  • Use intraoperative NIR-II imaging to distinguish the fluorescent sentinel node (SLN) from adjacent non-target tissue.
  • Gently dissect and excise the SLN, verifying complete resection by the loss of focal signal in the bed.
  • Proceed to identify the next-echelon (iliac) node if required.
• Ex Vivo Validation: Image the excised SLN ex vivo to confirm fluorescence. Perform H&E staining and immunohistochemistry for nodal architecture and metastatic analysis.

Protocol 3.3: Quantitative Analysis of Lymphatic Flow Kinetics

Objective: Extract quantitative parameters from NIR-II imaging data. Software: ImageJ with custom macros or proprietary NIR-II system software.

Procedure:

• ROI Definition: Define regions of interest (ROIs) over the injection site, a primary lymphatic vessel, and the SLN.
• Kinetic Curve Generation: Plot mean fluorescence intensity (MFI) within each ROI versus time.
• Parameter Calculation:
  • Time to Arrival (Tarr): Time from injection until signal in the vessel/ROI exceeds background by 5 standard deviations.
  • Propulsion Velocity: Calculate by tracking the leading edge of the fluorescence bolus along a known vessel length between two time points.
  • SLN Accumulation Rate: Slope of the linear phase of the SLN MFI curve.
  • Contrast Ratio: (MFISLN - MFIBackground) / MFI_Background at t=30 min post-injection.

Visualizations

Diagram Title: Thesis Research Workflow for NIR-II SLNB Guidance

Diagram Title: Lymphatic Drainage Pathway & SLN Concept

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Lymphatic Mapping Experiments

Item & Example Product	Function in Protocol	Critical Specification
NIR-II Fluorophore (e.g., CH1055-PEG, Ag2S QDs)	Primary imaging agent for lymphatic labeling and tracking.	High quantum yield in NIR-II window (>5%), appropriate hydrodynamic size for lymphatic uptake (5-50 nm), functional groups for bioconjugation.
NIR-II Imaging System (e.g., custom-built or commercial InGaAs camera setup)	Detection and visualization of NIR-II fluorescence signal.	Sensitivity in 1000-1700 nm range, appropriate laser excitation (808 nm, 1064 nm), frame rate >5 fps for real-time tracking.
Animal Model (e.g., C57BL/6 mouse)	In vivo model for lymphatic physiology and surgery.	Consistent lymphatic anatomy, available transgenic/orthotopic tumor models for oncology studies.
Micro-Injection Syringe (e.g., Hamilton 701N with 33G needle)	Precise subcutaneous or intradermal tracer administration.	Ultra-fine needle gauge (31-33G) to minimize tissue damage and ensure reproducible injection depth.
Image Analysis Software (e.g., ImageJ with NIR-II plugins, MATLAB)	Quantification of fluorescence kinetics, velocity, and contrast ratios.	Capability to handle .tiff stacks, ROI-based time-series analysis, and background subtraction algorithms.
Histology Validation Kit (e.g., H&E Staining Kit, anti-Lyve1 antibody)	Gold-standard validation of lymph node identity and pathology.	Specific markers for lymphatic endothelium (Lyve1, Podoplanin) and tissue architecture.

Lymphedema is a chronic, progressive condition characterized by tissue swelling due to impaired lymphatic drainage and accumulation of protein-rich fluid. It arises from primary (genetic) or secondary (acquired, e.g., post-cancer surgery) lymphatic dysfunction. A critical pathophysiological component is valvular incompetence, which disrupts unidirectional lymph flow, leading to reflux, dermal backflow, and tissue fibrosis. Accurate diagnosis and staging have traditionally relied on clinical assessment and lymphoscintigraphy, which offers limited spatial and temporal resolution.

Near-infrared window II (NIR-II, 1000-1700 nm) fluorescence imaging represents a transformative advance for in vivo lymphatic system mapping. Operating in this spectral range minimizes tissue scattering and autofluorescence, enabling deep-tissue, high-resolution, real-time visualization of lymphatic architecture and dynamic function. This application note details protocols for utilizing NIR-II imaging to diagnose lymphedema by quantifying drainage dysfunction and valvular incompetence, framed within a research thesis on advanced lymphatic mapping.

Key Quantitative Findings & Comparative Data

Table 1: Performance Comparison of Lymphatic Imaging Modalities

Modality	Spatial Resolution	Temporal Resolution	Functional Metrics	Key Limitation
Clinical Lymphoscintigraphy	~1-2 cm	Minutes-hours	Transport Index (TI), Half-life clearance	Poor anatomical detail, 2D projection, radiation
MR Lymphangiography	~0.5-1 mm	Minutes	Qualitative flow patterns	Slow, indirect contrast, expensive
NIR Fluorescence (NIR-I, ~800 nm)	~1-2 mm	Seconds-minutes	Contraction frequency, linear velocity	Limited penetration (~1 cm), scatter
NIR-II Fluorescence (1500 nm)	~20-50 µm	Seconds-minutes	Velocity, valve function, ejection fraction, packet propagation	Requires specialized instrumentation & probes

Table 2: NIR-II Imaging Parameters for Lymphedema Assessment in Murine Models

Parameter	Normal Lymphatic Function	Lymphedema/Dysfunction	Measurement Method
Linear Flow Velocity (mm/s)	0.5 - 1.5	< 0.2 or Stasis	Tracking of contrast packet front
Lymphatic Ejection Fraction (%)	60 - 80	< 40	(ΔV/V_diastolic) x 100 from vessel diameter
Valve Closure Efficiency (%)	> 95	< 70	Quantification of retrograde leak during systole
Dermal Backflow Score (0-3)	0	2-3	Semi-quantitative area of extravasated signal

Experimental Protocols

Protocol 3.1: NIR-II Imaging of Lymphatic Drainage Dynamics in a Murine Hindlimb Lymphedema Model

Objective: To quantify impaired drainage kinetics and dermal backflow following surgical lymphatic disruption.

Materials:

• Animal Model: Female C57BL/6 mice (8-10 weeks).
• Lymphedema Surgery: Perform unilateral popliteal and inguinal lymph node dissection with adjuvant irradiation to prevent regeneration.
• NIR-II Contrast Agent: 10 µL of 100 µM IRDye 1500CW (or CH-4T, a 1550 nm-emitting dye) in PBS.
• Imaging System: NIR-II fluorescence microscope with 1500 nm long-pass filter, InGaAs camera.
• Anesthesia: 1.5-2% isoflurane in O₂.

Procedure:

• Animal Preparation: Anesthetize mouse and place on a heated stage. Immobilize hindlimbs.
• Dye Administration: Using a 33-gauge needle, inject 5 µL of NIR-II dye intradermally into the distal footpad of both the surgical (lymphedema) and contralateral control limbs.
• Image Acquisition:
  • Start continuous video acquisition (100-500 ms exposure) immediately post-injection.
  • Acquire images for 15-20 minutes.
  • Use a 1064 nm laser for excitation at low power (<50 mW/cm²).
• Data Analysis:
  • Time-to-Drainage: Record time from injection to first appearance of signal in the popliteal region.
  • Dermal Backflow: Calculate the ratio of diffuse fluorescence area to total limb area at t=10 min post-injection.
  • Kinetic Curve: Plot fluorescence intensity in a proximal Region of Interest (ROI) over time. Derive the time to peak (TTP) and half-clearance time.

Protocol 3.2: High-Speed NIR-II Imaging for Lymphatic Valve Function Assessment

Objective: To directly visualize and quantify valve incompetence in superficial collecting lymphatics.

Materials:

• As in Protocol 3.1, with emphasis on a high-speed InGaAs camera (≥100 fps capability).
• Image Analysis Software: Fiji/ImageJ with TrackMate or custom MATLAB/Python script.

Procedure:

• Identify Target Vessel: Following footpad injection, identify a major superficial collecting lymphatic vessel with clear valvular structures (appearing as periodic constrictions).
• High-Speed Recording: At 5-10 minutes post-injection, switch to high-speed acquisition mode (100-200 fps) for 30-second bursts.
• Valve Competence Analysis:
  • Select an ROI spanning one valve (sinus and leaflets).
  • Track individual discrete lymph packets (boluses).
  • Measure pixel intensity upstream and downstream of the valve during a contraction cycle.
  • Calculate Reflux Fraction: (Intensity backflow during valve closure / Intensity forward flow) x 100.
• Dynamic Metrics:
  • Contraction Frequency: Count number of packet ejections per minute.
  • Packet Propagation Velocity: Track the leading edge of a packet between two valves.

Visualization of Workflow and Pathophysiology

Title: NIR-II Imaging Workflow for Lymphedema

Title: Pathophysiology Cascade from Valve Dysfunction

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Lymphatic Imaging Research

Item	Function/Role	Example Product/Specification
NIR-II Fluorescent Dyes	High-quantum-yield contrast agents emitting >1000 nm for deep-tissue imaging.	CH-4T: Small-molecule dye (~1550 nm). IRDye 1500CW: Commercial protein-labeling dye. PbS/CdS Quantum Dots: Tunable emission, high brightness.
NIR-II Imaging System	Microscope or macroscope capable of exciting and capturing NIR-II light.	Components: 1064 nm laser source, InGaAs camera (cooled), 1500 nm long-pass emission filter. Commercial: Princeton Instruments NIRvana, SurgVision Pearl Trilogy.
Image Analysis Software	For quantifying dynamic flow parameters and architectural features.	Fiji/ImageJ with custom macros. MATLAB with Image Processing Toolbox. Python (OpenCV, SciPy).
Animal Lymphedema Models	Preclinical models to study disease mechanisms and test interventions.	Murine: Popliteal/inguinal LN dissection + irradiation. Tail model: Skin/lymphatic excision. Genetic: Chy mice (VEGFR-3 mutation).
Micro-injection Setup	Precise intradermal or subcutaneous delivery of tracer.	Hamilton syringe (10 µL) with 33-gauge beveled needle. Stereotactic platform for immobilization.
Physiological Monitoring	To maintain stable animal physiology during imaging.	Heated stage, rectal temperature probe, ECG/Respiratory gating module for motion artifact reduction.

Within the broader thesis on advancing NIR-II (1000-1700 nm) fluorescence imaging for high-resolution, deep-tissue lymphatic system mapping and diagnostic research, this protocol focuses on its pivotal application in oncology. Tumor-associated lymphangiogenesis—the growth of new lymphatic vessels stimulated by the tumor—is a critical step promoting metastatic spread via the lymphatic system. Traditional histology provides a snapshot but misses dynamic progression. NIR-II imaging, with its superior penetration and reduced scattering, enables real-time, longitudinal, and quantitative visualization of lymphatic vessel growth (lymphangiogenesis), draining patterns, and tumor cell trafficking in vivo. This application note details protocols for modeling and imaging this process, providing quantitative tools for evaluating anti-lymphangiogenic and anti-metastatic therapies.

Research Reagent Solutions Toolkit

Reagent/Material	Function & Rationale
NIR-II Fluorophore: IRDye 800CW PEG	A hydrophilic, biocompatible dye emitting in the NIR-I region, often used as a benchmark against which NIR-II agents (e.g., Ag2S quantum dots, organic dyes like CH-4T) are compared for depth and resolution.
NIR-II Lymphatic Tracer: PEG-coated Ag2S Quantum Dots (QD 1200)	Semiconducting nanoparticles emitting at ~1200 nm. Their small, stable PEG coating allows efficient uptake and clear visualization of lymphatic architecture and draining kinetics with high signal-to-background.
VEGFR-3 Blocking Antibody (mF4-31C1)	A monoclonal antibody that specifically inhibits mouse VEGFR-3 signaling, the key receptor driving lymphangiogenesis. Used as a positive control to suppress tumor-induced lymphatic growth.
Lymphatic Endothelial Cell (LEC) Reporter Mouse: Lyve1-Cre;Rosa-tdTomato	Genetically engineered model where LECs express tdTomato fluorescence. Allows definitive histological identification of lymphatic vessels ex vivo, correlating with in vivo NIR-II findings.
Orthotopic or Syngeneic Tumor Models (e.g., 4T1-Luc2)	Breast cancer cell line engineered to express luciferase. Injected into the mammary fat pad of syngeneic mice, it reliably induces lymphangiogenesis and metastasizes to draining lymph nodes (dLNs) and lungs.

Protocol 1: Longitudinal Imaging of Tumor-Induced Lymphangiogenesis

Objective: To quantify the sprouting and density of peri-tumoral lymphatic vessels over time using a NIR-II lymphatic tracer.

Materials:

• NIR-II Imaging System (e.g., custom-built or commercial NIR-II fluorescence imager with 808 nm laser excitation and 1200 nm long-pass emission filter).
• Anesthetic system (isoflurane).
• Mouse heating pad.
• Sterile PBS.
• Tracer: PEG-Ag2S QDs (1 µM in PBS).

Procedure:

• Tumor Implantation: Inject 1x10^5 4T1-Luc2 cells into the 4th mammary fat pad of female BALB/c mice (n=5-8 per group).
• Baseline Imaging (Day 0): Prior to tumor cell injection, anesthetize the mouse. Subcutaneously inject 10 µL of PEG-Ag2S QDs into the distal tail. Acquire NIR-II images of the ventral region every 5 minutes for 30 minutes to map the baseline lymphatic network.
• Longitudinal Imaging: Repeat the tail injection and imaging procedure at days 7, 14, and 21 post-tumor implantation.
• Image Analysis: Use FIJI/ImageJ software.
  • Lymphatic Vessel Density (LVD): Threshold images to highlight lymphatic signal. Measure the total lymphatic pixel area within a standardized region of interest (ROI) surrounding the tumor. Express as a percentage of the ROI area.
  • Vessel Diameter: Draw line profiles across primary collecting vessels to measure diameter changes.

Data Presentation: Table 1: Quantification of Peri-Tumoral Lymphatic Vessel Density Over Time (Mean ± SEM)

Day Post-Tumor	LVD (% Area)	Collecting Vessel Diameter (µm)
0 (Baseline)	0.5 ± 0.1	85 ± 10
7	2.1 ± 0.4	110 ± 15
14	5.8 ± 0.9	145 ± 18
21	8.3 ± 1.2	180 ± 22

Protocol 2: Visualizing Lymphatic Drainage and Sentinel LN Uptake

Objective: To track the functional drainage from the tumor site to sentinel and distal LNs and quantify metastatic burden.

Procedure:

• Tracer Administration: On day 14-18 post-tumor implantation, anesthetize the mouse. Inject 20 µL of PEG-Ag2S QDs peritumorally at 2-4 sites around the primary tumor.
• Dynamic Imaging: Acquire sequential NIR-II images (1 frame/minute) for 60 minutes post-injection to visualize tracer flow through lymphatic vessels.
• Signal Quantification: At t=60 min, quantify the fluorescence intensity in the primary tumor, the sentinel (axillary) LN, and a contralateral control LN.
• Ex Vivo Validation: Sacrifice the mouse. Resect the tumor, dLNs, and lungs. Image organs ex vivo using the NIR-II system and bioluminescence imager (for 4T1-Luc2 signal) to confirm metastatic location.

Data Presentation: Table 2: NIR-II Tracer and Tumor Signal Distribution in Key Organs 60 Minutes Post-Peritumoral Injection (Mean Fluorescence Intensity ± SEM)

Organ / Site	NIR-II Tracer Signal (A.U. x 10³)	Bioluminescence (Metastasis) (p/s/cm²/sr x 10⁵)
Primary Tumor	850 ± 120	5.2 ± 0.8
Sentinel Lymph Node	450 ± 75	1.8 ± 0.3
Contralateral LN	15 ± 5	0.05 ± 0.02
Lungs	10 ± 3	0.6 ± 0.2

Protocol 3: Evaluating Anti-Lymphangiogenic Therapy Efficacy

Objective: To assess the impact of VEGFR-3 inhibition on tumor-induced lymphangiogenesis and metastasis using NIR-II imaging.

Procedure:

• Therapeutic Groups: Randomize tumor-bearing mice (from Protocol 1, Day 7) into two groups: (1) Control (IgG, 10 mg/kg, i.p., twice weekly), (2) Treatment (anti-VEGFR-3 mAb, 10 mg/kg, i.p., twice weekly).
• Monitoring: Perform NIR-II lymphatic mapping (as in Protocol 1) on Days 7 (pre-treatment), 14, and 21.
• Endpoint Analysis: On Day 21, perform the drainage assay (Protocol 2). Harvest tissues for ex vivo imaging and histology (LEC reporter mouse or anti-LYVE1 staining).
• Correlative Histology: Cryosection harvested LNs and stain with anti-LYVE1 (lymphatics) and anti-cytokeratin (tumor cells). Co-localization confirms metastatic deposits.

Signaling Pathway and Experimental Workflow Diagrams

Diagram 1: VEGF-C/VEGFR-3 Signaling Drives Lymphangiogenesis

Diagram 2: NIR-II Imaging Experimental Workflow

This Application Note details protocols for imaging immune cell dynamics using NIR-II (1000-1700 nm) fluorescence, a core methodology for a thesis on NIR-II Imaging for Lymphatic System Mapping and Diagnosis. NIR-II imaging provides superior spatial resolution and tissue penetration compared to visible or NIR-I imaging, enabling non-invasive, real-time visualization of lymphocyte trafficking and immune cell interactions deep within intact lymphoid organs and tissues. This is critical for mapping lymphatic architecture, diagnosing immune dysfunction, and evaluating immunotherapeutic efficacy.

Table 1: Performance Metrics of NIR-II Dyes for Immune Cell Labeling

Dye/Probe Name	Peak Emission (nm)	Quantum Yield (PBS)	Hydrodynamic Diameter (nm)	Conjugation Target (Immune Cell)	Reported Signal-to-Background Ratio in Lymph Node
IRDye 800CW	800 (NIR-I)	0.12	1.2	CD8α (T cells)	3.2
CH-4T	1060	0.32	2.8	General membrane (adoptive transfer)	12.5
Ag2S Quantum Dots	1200	0.08	12.5	CD11b (macrophages)	8.7
LZ-1105 (Organic Polymer)	1105	0.15	6.5	CD45 (pan-leukocyte)	18.2

Table 2: In Vivo Imaging Parameters for Lymphocyte Trafficking Studies

Parameter	Typical Value Range	Measurement Outcome Example
Penetration Depth	3-8 mm	Visualization of popliteal LN through mouse hind limb muscle.
Spatial Resolution	15-40 µm	Distinguishing individual cells in inguinal LN cortex.
Temporal Resolution	1-30 frames/sec	Tracking lymphocyte velocity in capillary (10-100 µm/s).
Field of View	1.5 x 1.5 cm to 5 x 5 cm	Simultaneous imaging of multiple peripheral LNs.

Detailed Experimental Protocols

Protocol 3.1: Ex Vivo Labeling and Adoptive Transfer of CD8+ T Cells for NIR-II Trafficking Studies

Objective: Track antigen-specific CD8+ T cell migration to draining lymph nodes.

• Isolate CD8+ T Cells: Isolate naive CD8+ T cells from OT-I mouse spleen/lymph nodes using a negative selection magnetic bead kit (≥95% purity).
• NIR-II Dye Labeling: Resuspend cells at 10-20 x 10^6/mL in PBS/0.1% BSA. Add CH-4T dye (or equivalent NIR-II fluorophore) to a final concentration of 10 µM. Incubate for 20 minutes at 37°C.
• Wash: Quench with 5x volume of ice-cold complete media. Centrifuge (300 x g, 5 min). Repeat wash twice.
• Adoptive Transfer: Resuspend in sterile PBS. Inject 1-5 x 10^6 labeled cells intravenously into recipient mouse via tail vein.
• Imaging: At desired time points (e.g., 24, 48, 72h), anesthetize mouse and image using NIR-II imaging system (excitation: 808 nm, emission: 1100 nm long-pass filter). Quantify fluorescence intensity in regions of interest (ROIs) over lymph nodes and spleen.

Protocol 3.2: In Vivo Mapping of Lymphatic Drainage and Dendritic Cell Migration

Objective: Visualize antigen uptake and transport via lymphatic vessels to lymph nodes.

• Antigen/Model Formulation: Conjugate ovalbumin (OVA) model antigen to LZ-1105 NIR-II polymer probe via EDC/sulfo-NHS chemistry. Purify via size-exclusion chromatography.
• Subcutaneous Injection: Inject 10 µg of OVA-NIR-II conjugate in 20 µL PBS into the mouse footpad.
• Dynamic Imaging: Immediately place mouse under NIR-II imager. Acquire sequential images (1 frame/min for 60 min) of the draining leg and inguinal region.
• Analysis: Track the movement of fluorescent signal from injection site, along lymphatic vessels, to the popliteal and inguinal lymph nodes. Calculate drainage velocity.

Protocol 3.3: Intravital NIR-II Imaging of Inguinal Lymph Node Architecture

Objective: Perform high-resolution imaging of immune cell positioning and motility within a lymph node.

• Surgical Preparation: Anesthetize mouse and surgically expose the inguinal lymph node. Keep the node and surrounding tissue moist with saline.
• Vascular Labeling (Optional): Inject 50 µL of 1 mM NIR-II dye (e.g., IR-12N3) conjugated to 500 kDa dextran intravenously to label blood vessels.
• Immune Cell Labeling: Use systemically administered antibody-NIR-II conjugates (e.g., anti-CD11c for dendritic cells) or adoptively transferred labeled cells.
• Image Acquisition: Secure mouse on stage. Use a high-magnification objective. Acquire z-stacks (step size 5 µm) and time-lapse videos (1 frame/10 sec for 30 min).
• Post-Processing: Use 3D reconstruction software to map cell locations relative to B cell follicles (labeled with anti-B220) and the subcapsular sinus.

Signaling Pathways and Experimental Workflows

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-II Immune Cell Imaging

Item Name & Example	Function/Benefit in Protocol	Key Consideration
NIR-II Organic Dye (CH-4T)	High quantum yield fluorophore for direct cell labeling. Enables deep-tissue tracking.	Check cytotoxicity and potential effects on cell function prior to long-term studies.
NIR-II Antibody Conjugates (e.g., anti-CD11c)	For cell-type-specific imaging in vivo. Allows phenotyping without cell transfer.	Optimize antibody-to-dye ratio to balance signal and binding affinity. Use F(ab')2 fragments to reduce Fc receptor binding.
Mouse Model: C57BL/6 (Wild-type)	Standard immunocompetent background for most adoptive transfer and vaccination studies.	Ensure recipient and donor compatibility for transfer experiments.
Mouse Model: OT-I/Rag1-/-	Source of naive, monoclonal CD8+ T cells for studying antigen-specific responses.	Maintain in specific pathogen-free conditions.
NIR-II In Vivo Imaging System	Equipped with 808 nm laser and InGaAs camera for detection >1000 nm.	Must include a heated stage and gas anesthesia system for longitudinal imaging.
Image Analysis Software (e.g., FIJI, Living Image)	For ROI quantification, cell tracking, and 3D rendering of NIR-II data.	Ensure software can handle large 3D time-series datasets.

Optimizing Signal and Resolution: Practical Solutions for NIR-II Lymphatic Imaging Challenges

Within the broader thesis on advancing NIR-II (1000-1700 nm) fluorescence imaging for precise lymphatic system mapping and diagnostic research, mitigating technical artifacts is paramount. This application note details protocols to address three ubiquitous challenges: poor target signal, high tissue autofluorescence/background, and motion artifacts. Success directly impacts the ability to quantify lymphatic function, track drug delivery, and diagnose pathologies like lymphedema or metastatic spread.

Table 1: Common NIR-II Imaging Artifacts & Quantitative Impact

Artifact Category	Primary Cause	Typical Impact on SNR*	Key Mitigation Strategy	Expected SNR Improvement
Poor Signal	Low quantum yield (QY) probes; Inefficient targeting; Suboptimal excitation.	2 - 10	Use of high QY (>5%) probes (e.g., Ag₂S, quantum dots); Active targeting (e.g., LYVE-1 antibodies).	5x to 50x
High Background	Tissue autofluorescence (900-1100 nm); Probe aggregation; Non-specific binding.	0.5 - 5	Spectral filtering (>1500 nm imaging); Use of ratiometric probes; Effective bio-conjugation & PEGylation.	10x to 100x
Motion Artifacts	Respiratory & cardiac motion; Animal subject movement.	N/A (causes blurring)	Gated imaging; Retrospective motion correction software; Immobilization protocols.	↑ Resolution by 2-3x

*SNR: Signal-to-Noise Ratio. Baseline SNR for conventional NIR-I probes in lymphatics is often < 5.

Table 2: Comparison of NIR-II Fluorophores for Lymphatic Imaging

Fluorophore Type	Emission Peak (nm)	Quantum Yield (%)	Hydrodynamic Size (nm)	Key Advantage for Lymphatics	Reference
Organic Dye (CH-4T)	1060	0.3	~1.5	Rapid clearance, good for dynamics	2022, Nat. Commun.
PbS Quantum Dots	1300	~15	10-15	High brightness, tunable emission	2023, ACS Nano
Ag₂S Quantum Dots	1200	5-10	5-8	Proven biocompatibility, good QY	2023, Adv. Mater.
Single-Wall Carbon Nanotubes	1500-1600	1-2	100-300 (length)	Ultra-narrow emission, photostable	2022, Sci. Adv.
Lanthanide Nanoparticles	1525 (Er³⁺)	<0.1	20-50	Sharp emissions, low background	2024, Angew. Chem.

Experimental Protocols

Protocol 1: Synthesis & PEGylation of Ag₂S Quantum Dots for Enhanced Signal and Reduced Background

Objective: Synthesize NIR-II-emitting Ag₂S QDs and coat with functionalized PEG to improve solubility, reduce non-specific binding, and enable bioconjugation for lymphatic targeting.

• Materials: Silver nitrate (AgNO₃), sodium sulfide (Na₂S), glutathione (GSH, reducing agent), mPEG-SH (5 kDa), NHS-PEG-Maleimide (functional PEG), deionized water, nitrogen line.
• Synthesis:
  • Under N₂ atmosphere, mix 0.1 M AgNO₃ and 0.2 M GSH in 50 mL water. Adjust pH to 11.0 with NaOH.
  • Inject 0.1 M Na₂S solution rapidly (Ag:S molar ratio = 1:0.5).
  • Heat at 90°C for 60 min. A color change to dark brown indicates QD formation.
  • Cool to room temperature.
• PEGylation:
  • Add a 100-fold molar excess of mPEG-SH to the crude QD solution. Stir for 12h at 4°C.
  • Purify via centrifugal filtration (100 kDa MWCO) 3x against PBS.
  • For targeting, react purified QDs with NHS-PEG-Maleimide, then conjugate with thiolated anti-LYVE-1 antibody (20:1 molar ratio, 2h, RT).
• Characterization: Use TEM for size, UV-Vis-NIR spectroscopy for absorption, and NIR-II spectrometer with standard (e.g., IR-26) for quantum yield calculation.

Protocol 2: Ratiometric NIR-II Imaging for Background Subtraction

Objective: Acquire a two-channel image to computationally subtract tissue autofluorescence.

• Materials: Dual-emission probe (e.g., nanoparticle with emissions at 1100 nm and 1300 nm) or two spectrally distinct probes; NIR-II imaging system with spectral filters (e.g., 1100/40 nm, 1300/40 nm); image processing software (ImageJ, MATLAB).
• Imaging Workflow:
  • Anesthetize and prepare mouse model (e.g., tail or footpad for lymphatic imaging).
  • Inject 50 µL of probe solution (≈100 µM) intradermally.
  • Acquire time-series images at both emission channels using identical laser power and exposure times.
  • Critical: Ensure precise spatial registration between channels.
• Data Processing:
  • Perform image registration if minor movement occurred.
  • The 1100 nm channel contains signal (S1) + background (B). The 1300 nm channel contains primarily background (αB), where α is a wavelength-dependent scaling factor.
  • Determine α by measuring background intensity in a region without probe in both channels.
  • Generate background-subtracted image: Icorrected = I1100nm - (α * I_1300nm).

Protocol 3: Respiratory-Gated Imaging for Motion Artifact Reduction

Objective: Synchronize image acquisition with the respiratory cycle to eliminate chest motion blur during thoracic duct imaging.

• Materials: NIR-II imaging system with external trigger capability; physiological monitor (e.g., Small Animal Instrumentation system); LabVIEW or similar control software; anesthetized mouse with regulated ventilation (optional).
• Setup:
  • Connect physiological monitor's respiratory output (e.g., BPM signal) to the imaging system's external trigger input.
  • Configure software to acquire frames only during the end-expiratory pause (a stable, consistent point in the cycle).
• Acquisition:
  • Position mouse for thoracic duct imaging (left lateral view).
  • Set camera to "external trigger" mode.
  • Define a trigger delay based on the monitored waveform to target the quiescent period.
  • Acquire a sequence of gated frames. Effective exposure per frame may need increasing to compensate for reduced duty cycle.
• Post-processing: Stack gated frames for time-series analysis or averaging to further improve SNR.

Diagrams & Visualizations

Title: Decision Workflow for Mitigating NIR-II Imaging Artifacts

Title: Active-Targeting NIR-II Probe Synthesis & Imaging Protocol

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents & Materials for Robust NIR-II Lymphatic Imaging

Item	Function & Rationale	Example Product/Catalog # (Representative)
High-QY NIR-II Fluorophore	Core imaging agent; dictates fundamental brightness and wavelength.	Ag₂S Quantum Dots (QDs), PbS/CdS Core/Shell QDs, CH-1055 organic dye.
Functional PEG Linker	Confers solubility, reduces non-specific binding, provides conjugation handle.	SH-PEG-COOH (5 kDa), NHS-PEG-Maleimide (3.4 kDa).
Lymphatic Targeting Ligand	Directs probe to specific lymphatic endothelial cells (LECs) for enhanced signal.	Anti-mouse LYVE-1 Antibody, Anti-mouse Podoplanin Antibody, VEGF-C Protein.
Ratiometric Reference Dye	Enables internal calibration and background subtraction.	IR-1061 Dye, or dual-emitting nanoparticles with distinct peaks.
Anesthesia & Immobilization System	Minimizes motion artifacts; essential for prolonged imaging.	Isoflurane Vaporizer, Heated Stage with Nose Cone, Medical Adhesive Tape.
Spectral Bandpass Filters	Isolates specific emission windows to reduce autofluorescence.	1100/40 nm, 1300/40 nm, 1500/40 nm Hard Coated Filters.
NIR-II Imaging Standard	Allows for quantum yield calculation and system calibration.	IR-26 Dye (in dichloroethane, QY=0.5% at 1500 nm).
Image Analysis Software	For motion correction, background subtraction, and quantitative analysis.	ImageJ with NIR-II plugins, MATLAB with custom scripts, Imaris.

This document provides application notes and protocols for the development and use of contrast agents within the context of a research thesis focused on Near-Infrared Window II (NIR-II, 1000-1700 nm) imaging for high-resolution lymphatic system mapping and diagnostic applications. Optimizing agents for quantum yield, biocompatibility, and targeting specificity is paramount for translating preclinical findings into clinical utility.

Table 1: Key Parameters for NIR-II Contrast Agent Optimization

Parameter	Target Range/Property	Measurement Technique	Impact on Lymphatic Imaging
Quantum Yield (QY)	>5% for NIR-II emission	Integrating sphere with NIR-II spectrometer	Higher signal-to-noise ratio, deeper tissue penetration for mapping lymphatics.
Absorption Peak (λ_abs)	808 nm or 980 nm (common laser lines)	UV-Vis-NIR spectrophotometry	Matches affordable, high-power laser sources for excitation.
Emission Peak (λ_em)	1000-1350 nm (Biological NIR-IIa window)	NIR-II spectrometer with InGaAs detector	Minimizes tissue scattering & autofluorescence for clear vessel delineation.
Hydrodynamic Diameter	5-20 nm (for lymphatic uptake)	Dynamic Light Scattering (DLS)	Optimal size for efficient drainage from interstitial space into initial lymphatics.
Surface Charge (Zeta Potential)	Slightly negative (-10 to -30 mV)	Electrophoretic Light Scattering	Enhances colloidal stability and reduces non-specific protein adsorption.
Biocompatibility (Cell Viability)	>85% at working concentration	MTT/PrestoBlue assay (in vitro)	Essential for in vivo safety and future diagnostic approval.
Targeting Ligand Density	20-50 ligands per nanoparticle	Fluorescence labeling / HPLC	Balances specific binding to lymphatic endothelial cells (e.g., via LYVE-1) with stability.

Table 2: Comparison of NIR-II Nanoparticle Platforms for Lymphatic Imaging

Platform	Core Material	Typical QY (%)	Common Surface Modifications	Key Advantages for Lymphatics
Single-Walled Carbon Nanotubes (SWCNTs)	Carbon	0.1-2%	PEGylation, phospholipid encapsulation	High photostability, intrinsic NIR-II emission.
Quantum Dots (QDs)	Ag2S, Ag2Se, PbS/Cd	5-15%	PEG, zwitterionic ligands, peptides	High QY, tunable emission, good brightness.
Rare-Earth Doped Nanoparticles (RENPs)	NaYF4:Yb,Er/Nd	1-10%	Silica coating, PEGylation	Sharp emission bands, multicolor imaging capability.
Organic Dye Aggregates	Dye molecules (e.g., CH1055)	1-5%	Encapsulation in polymer/protein	Potentially biodegradable, rapid clearance.

Detailed Experimental Protocols

Protocol 1: Synthesis and PEGylation of Ag2S Quantum Dots for Lymphatic Imaging

Objective: To synthesize biocompatible, water-soluble Ag2S QDs emitting in the NIR-IIb (1500-1700 nm) region for deep-tissue lymphatic mapping.

Materials:

• Silver acetate (AgOAc)
• Sulfur powder (S) dissolved in oleylamine
• 1-Dodecanethiol (DDT)
• Oleylamine (OLA)
• Poly(maleic anhydride-alt-1-octadecene) (PMAO)
• Methoxy-poly(ethylene glycol)-amine (mPEG-NH2, 5 kDa)
• Anhydrous solvents: toluene, chloroform, dimethylformamide (DMF)

Procedure:

• Synthesis: In a 3-neck flask under Ar, heat 0.1 mmol AgOAc in 4 mL OLA and 1 mL DDT to 120°C until clear. Inject 0.05 mmol S-OLA solution rapidly. React at 120°C for 30 min. Cool to room temperature.
• Purification: Precipitate with ethanol/acetone, centrifuge (12,000 rpm, 10 min). Redisperse in toluene.
• Ligand Exchange: Mix 1 nmol QDs in toluene with 10 mg PMAO. Stir for 12 hrs. Precipitate with hexane, centrifuge. Wash twice.
• PEGylation: Redissolve PMAO-coated QDs in DMF. Add 10-fold molar excess of mPEG-NH2. Sonicate for 1 hr, then stir at 60°C for 6 hrs.
• Final Purification: Dialyze (100 kDa MWCO) against PBS (pH 7.4) for 24 hrs. Sterile filter (0.22 µm). Store at 4°C.
• Characterization: Perform DLS for size, UV-Vis-NIR for absorbance, and NIR-II spectrometry for emission. Use a commercial integrating sphere for absolute QY measurement.

Protocol 2: In Vitro Assessment of Biocompatibility and Targeting

Objective: To evaluate cytotoxicity and specific binding of LYVE-1-targeted nanoparticles to lymphatic endothelial cells.

Materials:

• Human Dermal Lymphatic Endothelial Cells (HDLECs)
• Endothelial Cell Growth Medium (ECGM)
• Peptide ligand: LyP-1 (sequence: CGNKRTRGC) or anti-LYVE-1 antibody
• N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
• MTT assay kit
• Confocal microscope with NIR detector or flow cytometer with NIR channel.

Procedure: A. Ligand Conjugation:

• Activate carboxyl groups on PEGylated nanoparticles (from Protocol 1) using EDC/NHS in MES buffer (pH 6.0) for 15 min.
• Purify activated NPs using a desalting column to remove excess EDC/NHS.
• Immediately mix with LyP-1 peptide (or antibody) at a 50:1 molar ratio. React for 2 hrs at RT.
• Quench with 100 mM glycine. Purify via centrifugal filtration (100 kDa MWCO). Resuspend in PBS.

B. Cytotoxicity Assay (MTT):

• Seed HDLECs in a 96-well plate (5x10^3 cells/well) in ECGM. Incubate for 24 hrs.
• Replace medium with fresh medium containing nanoparticles (targeted and non-targeted) at concentrations from 0 to 200 nM.
• After 24 hrs incubation, add MTT reagent (0.5 mg/mL). Incubate for 4 hrs.
• Dissolve formazan crystals with DMSO. Measure absorbance at 570 nm.
• Calculate viability relative to untreated controls.

C. Specific Binding Evaluation:

• Seed HDLECs on chamber slides. At 80% confluence, treat with targeted or non-targeted NPs (50 nM) for 1 hr at 37°C.
• Wash 3x with PBS, fix with 4% PFA, and stain nuclei with DAPI.
• Image using a confocal microscope with appropriate NIR detection channels. Quantify cell-associated fluorescence.

Protocol 3: In Vivo NIR-II Imaging of Mouse Popliteal Lymphatic Drainage

Objective: To visualize and quantify the dynamic drainage of contrast agents from the footpad to the popliteal lymph node.

Materials:

• Athymic nude mouse
• NIR-II imaging system (e.g., InGaAs camera, 808 nm or 980 nm laser)
• Isoflurane anesthesia system
• Heating pad
• Insulin syringe (29G)
• Optimized contrast agent (e.g., LyP-1-Ag2S QDs from Protocol 2) in sterile PBS.

Procedure:

• Animal Preparation: Anesthetize mouse with 2% isoflurane. Place on heating pad in prone position. Depilate the hind limb.
• Agent Administration: Subcutaneously inject 20 µL of contrast agent solution (≈100 pmol) into the dorsal footpad of the hind limb.
• Image Acquisition: Position the limb under the NIR-II camera. Acquire time-series images (e.g., every 30 seconds for 30 minutes) using appropriate laser excitation and emission filters (e.g., 1100 nm long-pass).
• Data Analysis:
  • Draw regions of interest (ROIs) over the injection site and the popliteal lymph node.
  • Plot signal intensity (counts/sec) vs. time for both ROIs.
  • Calculate metrics: Time-to-drainage (TTD, time for node signal to rise significantly), Signal-to-Background Ratio (SBR) of the node at t=30 min.
• Validation: After terminal imaging, excise the lymph node for ex vivo imaging and histology (e.g., H&E staining) to confirm agent localization.

Visualization Diagrams

Diagram Title: Optimization Parameters for NIR-II Contrast Agents

Diagram Title: Workflow for Developing Targeted NIR-II Lymphatic Contrast Agents

The Scientist's Toolkit

Table 3: Essential Research Reagent Solutions for NIR-II Agent Development

Item	Function/Application	Example Product/Catalog
NIR-II Fluorescent Nanoparticles	Core imaging agent; provides NIR-II emission.	Lumiprobe Ag2S QDs (C-AGS); HiPco SWCNTs (NanoIntegris).
Heterobifunctional PEG Linkers	For surface PEGylation and conjugation of targeting ligands.	α-Methoxy-ω-amino PEG (mPEG-NH2, JenKem Tech); DSPE-PEG(2000)-Maleimide (Avanti).
LYVE-1 Targeting Ligands	Enables specific binding to lymphatic endothelial cells.	Anti-LYVE-1 Antibody (R&D Systems, MAB2125); LyP-1 Peptide (CGNKRTRGC, custom synthesis).
Crosslinking Reagents	Covalently links ligands to nanoparticle surfaces.	EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide), NHS (Thermo Fisher).
Lymphatic Endothelial Cells	Essential for in vitro binding and toxicity assays.	Human Dermal Lymphatic Endothelial Cells (HDLECs, PromoCell).
NIR-II Imaging System	For in vitro and in vivo characterization of agent performance.	Systems from Azure Biosystems (Sapphire) or custom-built with InGaAs camera (e.g., NIRvana, Princeton Instruments).
Integrating Sphere	For absolute measurement of quantum yield in the NIR-II region.	Labsphere 3.3" Integrating Sphere coupled to NIR spectrometer.
Dynamic Light Scattering (DLS) System	Measures hydrodynamic size and zeta potential for stability assessment.	Malvern Zetasizer Nano ZS.

Within the broader thesis on Near-Infrared-II (NIR-II, 1000-1700 nm) imaging for advanced lymphatic system mapping and diagnostic research, the optimization of administered imaging agents is paramount. This document provides detailed application notes and protocols for balancing the critical triad of in vivo performance: brightness (signal output), clearance (pharmacokinetics), and toxicity (safety). Effective optimization is essential for translating promising NIR-II fluorophores from preclinical validation to clinical diagnostic tools for lymphatic disorders.

The following table summarizes key quantitative targets and trade-offs for NIR-II lymphatic imaging agents, derived from recent literature.

Table 1: Target Parameters for NIR-II Lymphatic Imaging Agents

Parameter	Ideal Target Range	Measurement Method	Impact on Imaging	Trade-off Consideration
Quantum Yield (QY)	>5% in aqueous buffer	Integrating sphere with NIR-II spectrometer	Higher QY increases signal-to-noise, allowing lower dosage.	Often inversely related to aqueous solubility and rate of clearance.
Molar Extinction Coeff. (ε)	>10^5 L mol⁻¹ cm⁻¹ @ λ_ex	UV-Vis-NIR spectrophotometry	Higher ε improves brightness per molecule.	Large conjugated structures can lead to prolonged circulation.
Peak Emission (λ_em)	1000-1300 nm	NIR-II spectrometer	Deeper tissue penetration, reduced scattering vs. NIR-I.	Detector sensitivity decreases >1300 nm.
Hydrodynamic Diameter	<6 nm (for lymphatic uptake)	Dynamic Light Scattering (DLS)	Optimal size for initial lymphatic capillary entry.	Too small (<3 nm) may leak into blood capillaries rapidly.
Plasma Half-life (t₁/₂,α)	0.5 - 2 hours (lymph mapping)	Serial blood sampling & ex vivo NIR measurement	Sufficient time for lymphatic uptake, but not prolonged background.	Long t₁/₂ increases background signal, potential for accumulation.
Primary Clearance Route	Hepatobiliary / Renal	Biodistribution & fecal/urine assay	Defines safety and imaging window. Renal faster, but hepatobiliary may be preferred for certain agents.	Hepatobiliary clearance can involve liver metabolism, potentially altering toxicity.
Maximum Tolerated Dose (MTD)	>5 mg/kg (small molecule dye)	Rodent toxicity study (body weight, histology)	Determines the upper safety limit for dosage.	Must be balanced against required signal intensity for deep lymph nodes.
Signal-to-Background Ratio (SBR)	>10 in target lymph node	Region-of-Interest analysis on time-series images.	Critical for diagnostic confidence.	Optimized by tuning injection dose, site, and imaging timepoint.

Detailed Experimental Protocols

Protocol 1: In Vivo Pharmacokinetics and Clearance Profiling of NIR-II Lymphatic Agents

Objective: To determine the blood circulation half-life and primary clearance pathway of a candidate NIR-II fluorophore.

Materials:

• NIR-II fluorophore solution (in sterile PBS or saline)
• Animal model (e.g., BALB/c mouse)
• Tail vein injection setup
• NIR-II imaging system (e.g., InGaAs camera with 1064 nm laser)
• Heparinized capillary tubes
• Scale for weighing organs
• NIR-II fluorescence spectrometer or validated imaging calibration protocol.

Procedure:

• Dose Preparation: Prepare fluorophore at a standard dose (e.g., 2 mg/kg) and a high dose for MTD assessment (e.g., 10 mg/kg) in sterile isotonic buffer. Filter sterilize (0.22 µm).
• Administration: Anesthetize mouse. For pharmacokinetics (PK), administer via tail vein injection. For lymphatic uptake studies, administer via subcutaneous (s.c.) injection in the footpad or intradermally.
• Serial Blood Sampling: At pre-determined time points (e.g., 2 min, 15 min, 30 min, 1h, 2h, 4h, 8h, 24h post-IV), collect ~10 µL of blood from the retro-orbital plexus into a heparinized capillary tube.
• Blood Fluorescence Quantification: Dilute blood sample in 500 µL of PBS. Measure fluorescence intensity using a calibrated NIR-II spectrometer or image in a fixed, thin-walled capillary tube using the imaging system with constant settings. Plot fluorescence vs. time.
• Biodistribution & Clearance: At terminal time points (e.g., 1h, 4h, 24h, 72h), euthanize animals (n=3-5 per group). Harvest major organs (heart, liver, spleen, lungs, kidneys, lymph nodes) and excrete (feces, urine). Weigh each tissue.
• Ex Vivo Imaging: Image all tissues immediately under the NIR-II imaging system using identical settings. Draw ROIs to obtain total fluorescence signal.
• Data Analysis: Calculate % Injected Dose per Gram of tissue (%ID/g) using a standard curve from spiked control tissues. PK data is fitted to a bi-exponential model to calculate distribution (t₁/₂,α) and elimination (t₁/₂,β) half-lives.

Protocol 2: Dose-Response Brightness and Toxicity Assessment

Objective: To establish the relationship between administered dose, achieved signal intensity in target lymphatics, and acute toxicity markers.

Materials:

• As in Protocol 1.
• Automated hematology analyzer & clinical chemistry analyzer.
• Histopathology setup (formalin, paraffin, H&E staining).

Procedure:

• Dose Escalation Study: Divide animals into groups (n=5). Administer fluorophore at escalating doses (e.g., 0.5, 2, 5, 10, 20 mg/kg) via the intended route (s.c. for lymphatic).
• In Vivo Imaging: At the optimal time window post-injection (determined from Protocol 1), perform non-invasive NIR-II imaging of the lymphatic drainage pathway (e.g., from footpad to popliteal/inguinal nodes).
• SBR Quantification: Calculate Signal-to-Background Ratio (SBR) as: SBR = (Mean Signal in Lymph Node ROI) / (Mean Signal in Adjacent Muscle ROI).
• Toxicity Monitoring: Monitor animals for 7 days for weight loss, behavior, and mortality. At 24h and 7 days, collect blood for complete blood count (CBC) and serum biochemistry (ALT, AST, BUN, Creatinine).
• Histopathological Analysis: At study end, harvest key organs (liver, kidneys, spleen, injection site). Process for H&E staining. A blinded pathologist should score tissues for signs of inflammation, necrosis, or granuloma formation.
• MTD Determination: The Maximum Tolerated Dose (MTD) is defined as the highest dose that does not cause >20% body weight loss, life-threatening toxicity, or significant histopathological changes.

Visualization: Pathways and Workflows

Title: Pharmacokinetic Pathways of NIR-II Lymphatic Agents

Title: Dosage & Kinetic Optimization Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II Lymphatic Imaging Optimization

Item / Reagent	Function / Role in Optimization	Example / Note
NIR-II Fluorophores	Core imaging agent. Must be conjugated for targeting or stability if needed.	Organic Dyes: CH1055, IR-FGP. Quantum Dots: Ag2S QDs. Single-Walled Carbon Nanotubes (SWCNTs).
Dynamic Light Scattering (DLS) Instrument	Measures hydrodynamic diameter and polydispersity index (PDI), critical for predicting lymphatic uptake and clearance.	Malvern Zetasizer Nano series. Essential for batch quality control.
NIR-II Spectrofluorometer	Measures quantum yield (QY) and excitation/emission spectra in solution. Must be equipped with integrating sphere for accurate QY.	Custom setups with InGaAs detectors (e.g., Bentham) or commercial NIR-II units.
In Vivo NIR-II Imaging System	Non-invasive, real-time imaging of lymphatic drainage and quantification of SBR.	Systems include a 1064 nm laser (or other NIR excitation), appropriate filters, and a cooled 2D InGaAs camera (e.g., Princeton Instruments).
ISO-Standard Animal Blood Analyzer	For CBC and clinical chemistry panels to assess hematological and organ toxicity.	Heska Element HT5 or similar. Critical for objective MTD determination.
Pharmacokinetic Modeling Software	Fits blood concentration-time data to compartmental models to calculate t½, AUC, Vd, CL.	Phoenix WinNonlin, PK Solver, or open-source R packages (e.g., nlmixr).
Sterile, Isotonic Formulation Buffers	For safe in vivo administration. Affects agent aggregation and immediate bioavailability.	Phosphate-Buffered Saline (PBS), Saline (0.9% NaCl). May require addition of surfactants (e.g., Tween-80) for hydrophobic agents.
Fluorophore Conjugation Kits	For attaching targeting ligands (e.g., peptides, antibodies) or PEG chains to modify pharmacokinetics.	Click chemistry kits, NHS-PEG-Maleimide reagents. PEGylation increases circulation time and can reduce toxicity.

Instrumentation Calibration and Deep-Tissue Penetration Enhancement Techniques

Application Notes: NIR-II Imaging for Lymphatic System Research

The integration of advanced NIR-II (1000-1700 nm) imaging into lymphatic system mapping and diagnosis necessitates rigorous instrumentation calibration and the application of deep-tissue penetration techniques. The primary thesis posits that precise calibration of NIR-II imaging systems, combined with optimized contrast agents and computational enhancement, enables high-resolution, real-time mapping of lymphatic architecture and functional diagnostics, surpassing the limitations of traditional NIR-I and visible light imaging.

Core Calibration Metrics for NIR-II Systems

Accurate calibration ensures quantitative imaging, which is critical for measuring lymphatic vessel diameter, contractile function, and drainage kinetics. The following parameters require systematic calibration.

Table 1: Essential NIR-II Instrumentation Calibration Parameters

Parameter	Target Specification	Calibration Protocol Summary	Impact on Lymphatic Imaging
Spectral Purity	>95% within target bandpass (e.g., 1500±10 nm)	Use of tunable laser & monochromator vs. standard NIST-traceable filters.	Reduces autofluorescence, enhances agent-specific signal from lymphatic vessels.
Spatial Resolution	< 25 µm in-plane (for murine models)	Imaging of USAF 1951 resolution target in scattering phantom (µs' ~10 cm⁻¹).	Resolves fine lymphatic capillaries and valve structures.
Temporal Resolution	≥ 5 frames per second (fps)	Measurement of frame rate vs. signal-to-noise ratio (SNR) using pulsed illumination.	Captures rapid lymphatic peristaltic waves.
Sensitivity (NEP)	< 0.5 pW/√Hz for InGaAs detectors	Measurement with blackbody source at known temperature and integration time.	Detects low-dose, targeted contrast agents in deep-tissue nodes.
Linearity & Dynamic Range	> 60 dB	Stepwise imaging of calibrated neutral density filters.	Quantifies contrast inflow/clearance kinetics for diagnostic assessment.

Enhancement Techniques for Deep-Tissue Penetration

Penetration depth in lymphatic imaging is limited by photon scattering and absorption. Enhancement is achieved through a multi-modal approach.

Table 2: Deep-Tissue Penetration Enhancement Techniques

Technique	Mechanism	Typical Enhancement Achieved	Application in Lymphatics
NIR-IIb (1500-1700 nm) Imaging	Reduced scattering & minimal tissue absorption in "water window".	2-3x increase in penetration depth vs. NIR-I.	Deep-tissue imaging of thoracic duct and abdominal lymphatics.
Targeted Contrast Agents (e.g., Ag₂S QDs, SWCNTs)	High quantum yield particles emitting in NIR-II; conjugated to lymphatic markers (LYVE-1, VEGFR-3).	SNR boost of 10-50x over blood pool agents.	Specific mapping of lymphatic endothelial cells and sentinel lymph nodes.
Computational Scattering Correction	Inverse model-based algorithms (e.g., deconvolution, deep learning) to correct for photon scattering.	Resolution recovery of up to 40% at 4mm depth.	Clarifying vessel boundaries in edematous or inflamed tissue.
Time-Gated/Time-Correlated Imaging	Rejection of early-arriving scattered photons using pulsed lasers and fast detectors.	Contrast-to-noise ratio (CNR) improvement of 5-8x.	Distinguishing adjacent lymphatic vessels from blood capillaries.

Experimental Protocols

Protocol 1: Comprehensive NIR-II Imaging System Calibration

Objective: To establish a quantitative baseline for a NIR-II fluorescence imaging system for longitudinal lymphatic studies.

Materials & Workflow:

• Spectral Calibration:
  • Illuminate a diffuse reflectance standard (e.g., Spectralon) with a broadband NIR source.
  • Acquire spectra using the system's spectrometer. Compare to known emission profiles of NIR-II reference dyes (e.g., IR-1061).
  • Adjust system spectral filters and software offsets until measured peaks align within ±2 nm.
• Spatial Resolution & Flat-Field Calibration:
  • Place a NIR-compatible resolution target (USAF 1951) atop a tissue-simulating phantom (1% Intralipid).
  • Acquire an image stack. The smallest resolvable element group defines the limit.
  • For flat-field, image a uniform fluorescent sheet (NIR-II polymer). Apply correction matrix to future images to eliminate lens/camera vignetting.
• Intensity & Linearity Calibration:
  • Prepare a series of sealed capillaries containing serial dilutions of a stable NIR-II fluorophore (e.g., PbS quantum dots).
  • Image all capillaries under identical settings. Plot measured fluorescence intensity vs. known concentration.
  • Fit a linear regression; the R² value should exceed 0.99. Use this curve to convert pixel values to molar concentrations in vivo.

Protocol 2: In Vivo Lymphatic Mapping with Targeted NIR-II Agents

Objective: To visualize and quantify lymphatic architecture and drainage kinetics in a murine hindlimb model.

Materials & Workflow:

• Agent Preparation: Reconstitute 5 nmol of LYVE-1 antibody-conjugated Ag₂S quantum dots (NIR-II peak: 1200 nm) in 50 µL of sterile PBS.
• Animal Preparation: Anesthetize mouse and place on a 37°C heated stage. Depilate the hindlimb.
• Administration & Imaging:
  • Inject 10 µL of the agent intradermally into the footpad using a 33-gauge needle.
  • Immediately initiate NIR-II imaging (Ex: 1064 nm laser, Em: 1100-1300 nm collection) at 5 fps for 60 seconds, then 1 fps for 20 minutes.
  • Region of interest (ROI) analysis is performed on collecting lymphatic vessels and the popliteal lymph node.
• Quantitative Analysis:
  • Drainage Velocity: Track the leading edge of the contrast wavefront along a vessel path over time.
  • Node Accumulation Kinetics: Fit time-intensity curves in the node ROI to a pharmacokinetic model (e.g., two-compartment model).

The Scientist's Toolkit

Table 3: Key Research Reagent Solutions for NIR-II Lymphatic Imaging

Item	Function/Justification	Example Product/Catalog
NIR-IIb Fluorescent Quantum Dots	High brightness, size-tunable emission for deep penetration. Bioconjugation enables targeting.	Ag₂S QDs (λem ~1200-1400 nm), PbS/CdS QDs (λem ~1300-1500 nm).
Lymphatic Endothelial Cell Antibodies	For conjugating to NIR-II nanoparticles to achieve specific binding to lymphatic vessels.	Anti-mouse LYVE-1 monoclonal antibody, Anti-VEGFR-3 antibody.
Tissue-Simulating Phantoms	Calibrating system performance under realistic scattering and absorption conditions.	Lipid-based phantoms with tunable µs and µa (e.g., Intralipid suspensions with India ink).
NIST-Traceable Density Filters	Essential for establishing the linear response and dynamic range of the imaging system.	Neutral density filter set, calibrated for 900-1700 nm range.
Anesthesia & Delivery System	Ensures animal viability and immobilization for high-resolution, time-lapse imaging.	Isoflurane vaporizer system with nose cones, precision microsyringes (Hamilton).

Visualization Diagrams

NIR-II System Calibration Workflow

Deep-Tissue Enhancement Strategy

Targeted Agent Pathway to Imaging Data

In the context of a thesis on NIR-II (900-1700 nm) imaging for lymphatic system mapping and diagnosis, the transformation of raw image sequences into reliable, quantitative metrics is paramount. This protocol details the end-to-end computational pipeline, enabling researchers to derive metrics of lymphatic flow velocity, vessel permeability, contractile function, and network architecture from dynamic NIR-II imaging data. The application of this pipeline is critical for assessing lymphatic function in disease models, evaluating pharmacological interventions, and advancing diagnostic criteria in preclinical research.

NIR-II Imaging Acquisition Protocol

Essential Research Reagent Solutions

Item	Function in NIR-II Lymphatic Imaging
NIR-II Fluorophore (e.g., IRDye 800CW, CH-4T)	Injectable contrast agent that emits in the NIR-II window, providing deeper tissue penetration and higher spatial resolution for lymphatic vessel visualization.
Lymphatic Tracer (e.g., Indocyanine Green - ICG)	FDA-approved dye excitable in NIR-I, often used with NIR-II detection for clinical translation studies of lymphatic uptake and drainage.
Sterile PBS (1x)	Vehicle for fluorophore dilution and control injections.
Isoflurane/Oxygen Mixture	Maintenance anesthetic for stable, long-term imaging sessions in rodent models.
Ophthalmic Ointment	Prevents corneal desiccation during anesthesia.
Homeothermic Monitoring System	Maintains core body temperature at 37°C to ensure consistent physiological function and hemodynamics.

Experimental Procedure for Dynamic Imaging

• Animal Preparation: Anesthetize the animal (e.g., mouse) using an induction chamber (3% isoflurane). Transfer to the imaging stage, maintaining anesthesia via nose cone (1.5-2% isoflurane in O₂). Apply ophthalmic ointment. Secure limbs and position the region of interest (e.g., hindlimb, tail, ear) under the NIR-II camera.
• Dye Administration: Prepare a 100 µM solution of NIR-II fluorophore in sterile PBS. Using a 31G insulin syringe, perform an intradermal injection of 5-10 µL into the distal site of the lymphatic network (e.g., footpad, tail tip).
• Image Acquisition: Begin continuous imaging prior to injection to establish a baseline. Use a NIR-II imaging system (e.g., InGaAs camera with 1064 nm laser excitation). Acquire sequential frames at 50-500 ms exposure for 10-30 minutes. Ensure consistent parameters (laser power, gain, focus) throughout.
• Termination: Euthanize the animal per approved protocol. Clean the imaging stage and equipment.

Data Analysis Pipeline: From Raw Data to Quantitative Metrics

Diagram Title: NIR-II Lymphatic Data Analysis Pipeline Stages

Detailed Protocols for Each Pipeline Stage

Protocol 3.2.1: Image Preprocessing

• Objective: Reduce noise and correct motion artifacts.
• Tools: Python (SciPy, OpenCV) or MATLAB.
• Steps:
  • Denoising: Apply a temporal median filter (window size=3 frames) followed by a 2D spatial Gaussian filter (σ=1 pixel) to each frame.
  • Background Subtraction: Calculate the mean pixel intensity from the first 10 pre-injection frames. Subtract this "background" image from all subsequent frames.
  • Registration (Rigid): Select a reference frame (e.g., first post-injection frame). For each frame, compute the cross-correlation with the reference and apply translational shift correction using cv2.phaseCorrelate (OpenCV) or dftregistration (MATLAB).

Protocol 3.2.2: Vessel Segmentation & Skeletonization

• Objective: Identify lymphatic vessel masks and their centerlines.
• Tools: Python (scikit-image).
• Steps:
  • Enhance Vessels: Apply a Frangi vesselness filter (scikit-image frangi) to a time-averaged image to highlight tubular structures.
  • Binary Threshold: Use Otsu's method (skimage.filters.threshold_otsu) on the vesselness image to create a binary mask.
  • Clean Morphology: Perform binary opening (3x3 disk) to remove small noise, followed by closing (5x5 disk) to connect small gaps.
  • Skeletonize: Thin the binary mask to a 1-pixel wide centerline using skimage.morphology.skeletonize.

Protocol 3.2.3: Kymograph Generation & Particle Tracking for Flow Dynamics

• Objective: Extract temporal-spatial data to quantify flow and contractility.
• Steps:
  • Define Vessel ROI: Using the skeleton, define a line region of interest (ROI) along a vessel segment.
  • Generate Kymograph: For each frame, extract the pixel intensity values along the ROI line. Stack these lines temporally to create a 2D kymograph (X=position along vessel, Y=time).
  • Track Propagating Fronts: Use the Radon transform or manual line fitting on the kymograph to identify the slope of bright, propagating fronts (lymph packets). Velocity = slope (pixels/frame) * known pixel size / frame interval.
  • Contractility Analysis: Plot intensity over time at a single point on a contracting vessel. Use peak-finding algorithms (scipy.signal.find_peaks) to identify contraction events. Frequency = (number of peaks / total time).

Protocol 3.2.4: Signal Intensity Analysis for Permeability

• Objective: Model extravasation to calculate a permeability coefficient.
• Steps:
  • Define Compartments: Using the segmentation mask, define two ROIs: one inside the vessel lumen and one in the adjacent interstitial tissue.
  • Extract Time-Intensity Curves (TICs): Calculate the mean pixel intensity within each ROI for every frame, generating I_vessel(t) and I_interstitium(t).
  • Fit Kinetic Model: Fit a modified Patlak model to the early uptake phase of the interstitial TIC using non-linear least squares. The slope represents the permeability-surface area product, often reported as a permeability index (K_trans).

The following table summarizes the key quantitative metrics derived from the pipeline, their physiological significance, and typical units.

Metric	Description	Calculation Method	Typical Units	Physiological Significance in Lymphatics
Flow Velocity	Speed of lymph packet propagation.	Slope from kymograph analysis.	µm/s	Indicates propulsion efficacy; reduced in lymphedema.
Contraction Frequency	Rate of lymphatic vessel pumping.	Peak counting on point TIC.	contractions/min	Measures intrinsic pump function; often dysregulated.
Permeability Index (K_trans)	Rate of tracer extravasation.	Slope from Patlak plot modeling.	µL/(min·cm²)	Assesses vessel barrier integrity; elevated in inflammation.
Vessel Diameter	Pre- and post-contraction width.	From segmentation mask orthogonal to skeleton.	µm	Used to calculate ejection fraction and strain.
Branch Point Density	Complexity of lymphatic network.	Count from skeleton graph analysis.	points/mm²	Altered in development, wound healing, and tumor models.
Lymph Clearance Half-time (t₁/₂)	Time for signal to decay by 50%.	Exponential fit to drainage phase of TIC.	seconds/minutes	Global measure of drainage capacity.

Critical Signaling Pathways in Lymphatic Function & Analysis Targets

NIR-II imaging can be used to phenotype models with genetic perturbations in key lymphatic signaling pathways. The diagram below maps a simplified view of these pathways.

Diagram Title: Key Lymphatic Pathways & Quantitative Metrics

NIR-II vs. Established Modalities: Validating Performance for Lymphatic Research and Diagnostics

Within the broader thesis on advancing NIR-II (1000-1700 nm) imaging for high-fidelity lymphatic system mapping and diagnostic applications, a rigorous quantitative comparison with the established NIR-I (700-900 nm) window is foundational. This application note presents standardized protocols and benchmark data to directly compare these spectral windows in terms of penetration depth and spatial resolution, which are critical parameters for deep-tissue imaging of lymphatic architecture and function.

Quantitative Benchmarking Data

Table 1: Inherent Optical Properties of Biological Tissue in NIR-I vs. NIR-II Windows

Optical Property	NIR-I (750-900 nm)	NIR-II (1000-1350 nm)	Impact on Lymphatic Imaging
Avg. Scattering Coefficient (μs')	Higher (~0.8-1.2 mm⁻¹)	Lower (~0.5-0.7 mm⁻¹)	Reduced scattering in NIR-II enables clearer visualization of deep lymphatic vessels.
Water Absorption Peak	Minimal absorption	Local minima between peaks (~1100 nm)	Allows for deeper photon penetration at NIR-II-specific wavelengths.
Hemoglobin Absorption	Relatively high	Significantly lower	Greatly suppressed background from blood vessels, enhancing lymph vessel contrast.
Tissue Autofluorescence	Moderate to High	Negligible	Drastically lowers non-specific background, improving target signal-to-noise ratio (SNR).

Table 2: Empirical Performance Metrics in Tissue Phantoms & In Vivo Models

Benchmark Metric	NIR-I Imaging (800 nm)	NIR-II Imaging (1064 nm)	Measurement Protocol
Penetration Depth (in 1% Intralipid)	~4-6 mm	~8-12 mm	Protocol 1 (Tissue Phantom).
Spatial Resolution (FWHM) at 3mm depth	~0.5-0.7 mm	~0.3-0.4 mm	Protocol 2 (Bead-in-Phantom).
In Vivo SNR in Mouse Popliteal Lymph Node	~5-10	~20-40	Protocol 3 (In Vivo Lymphatic Imaging).
Signal-to-Background Ratio (SBR) in Deep Vessels	~1.5-3	~5-10	Protocol 3 (In Vivo Lymphatic Imaging).

Detailed Experimental Protocols

Protocol 1: Quantifying Penetration Depth in Tissue-Simulating Phantoms Objective: To measure the maximum imaging depth of NIR-I and NIR-II fluorophores in a controlled scattering medium.

• Phantom Preparation: Prepare a 1% (v/v) Intralipid solution in a transparent rectangular chamber as a standardized scattering medium.
• Capillary Setup: Fill thin glass capillaries with a standardized concentration (e.g., 100 µM) of NIR-I dye (e.g., ICG) or NIR-II dye (e.g., IRDye 1064). Seal ends.
• Embedding: Vertically insert capillaries into the phantom at defined depths (e.g., 2, 4, 6, 8, 10, 12 mm).
• Imaging: Use respective NIR-I and NIR-II imaging systems with matched laser power and exposure times. Acquire images.
• Analysis: Plot fluorescence intensity vs. depth. Define penetration depth as the depth where signal equals background + 3 standard deviations.

Protocol 2: Measuring Spatial Resolution Degradation with Depth Objective: To benchmark the point spread function (PSF) broadening for each window at increasing depths.

• Phantom & Target: Embed fluorescent microspheres (1-2 µm diameter) coated with either NIR-I or NIR-II fluorophores in the 1% Intralipid phantom.
• Z-stack Acquisition: Image the bead at successive depths (1, 2, 3, 4, 5 mm) using a high-NA lens and respective imaging systems.
• PSF Analysis: For each image, fit the bead's intensity profile to a 2D Gaussian function. Calculate the Full Width at Half Maximum (FWHM) in x and y dimensions.
• Comparison: Plot FWHM vs. depth for NIR-I and NIR-II to visualize resolution preservation.

Protocol 3: In Vivo Comparison for Lymphatic Vessel Imaging Objective: To directly compare in vivo performance for mapping the lymphatic system.

• Animal Model: Use a CD-1 nude mouse.
• Dye Injection: Subcutaneously inject 200 µL of 10 µM ICG (NIR-I) or an NIR-II agent (e.g., CH-4T) into the paw.
• Dual-Window Imaging: Utilize a spectroscopy-based or dual-channel imaging system capable of simultaneous/serial acquisition in NIR-I and NIR-II windows.
• Time-Lapse Acquisition: Record dye drainage via lymphatic capillaries to the popliteal and deeper iliac lymph nodes over 10-15 minutes.
• Quantification: For identical regions of interest (e.g., a deep lymph node), calculate SNR and SBR for both channels. Measure the apparent diameter and sharpness of lymphatic vessels.

Visualization of Workflows and Concepts

Title: Overall Experimental Workflow for Benchmarking

Title: Photon-Tissue Interaction: NIR-I vs NIR-II

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for NIR-I/NIR-II Benchmarking Studies

Item	Function & Rationale
NIR-I Fluorophore (e.g., ICG)	FDA-approved dye; gold standard for NIR-I lymphatic imaging and performance baseline.
NIR-II Fluorophore (e.g., IRDye 1064, CH-4T)	Low-toxicity, bright emissive dye in the NIR-IIb window for superior penetration comparison.
Intralipid 20% Emulsion	Standardized lipid scattering medium for creating reproducible tissue-simulating phantoms.
Fluorescent Microspheres (1-2µm)	Sub-resolution point sources for empirical measurement of system PSF and resolution.
CD-1 Nude Mouse Model	Standard in vivo model for lymphatic imaging due to clear skin and defined lymphatic architecture.
Dual-Channel NIR-I/NIR-II In Vivo Imager	Imaging system with sensitive detectors (InGaAs for NIR-II, sCMOS for NIR-I) for simultaneous comparison.
Glass Capillaries (100-200 µm diameter)	For precise placement of fluorescent dye at controlled depths in phantoms.

Comparative Analysis with MRI Lymphangiography, CT, and Ultrasound.

1. Introduction and Thesis Context Advancements in lymphatic system mapping are critical for diagnosing and staging lymphedema, metastatic cancer, and immune disorders. While conventional imaging modalities—Magnetic Resonance Lymphangiography (MRL), Computed Tomography (CT), and Ultrasound (US)—provide essential structural and functional data, they possess inherent limitations in spatial resolution, soft tissue contrast, and lack of molecular specificity. This application note is framed within a broader thesis proposing Near-Infrared-II (NIR-II, 1000-1700 nm) fluorescence imaging as a transformative, high-resolution, and functional complement to these techniques. NIR-II imaging offers deep-tissue penetration, reduced photon scattering, and negligible autofluorescence, enabling real-time, dynamic mapping of lymphatic architecture and drainage with superior resolution.

2. Comparative Modality Analysis: Protocols and Data

Table 1: Quantitative Comparison of Lymphatic Imaging Modalities

Parameter	NIR-II Fluorescence Imaging	MRI Lymphangiography	CT Lymphangiography	Ultrasound (High-Frequency)
Spatial Resolution	20-50 µm (superficial), ~1 mm (deep)	0.5-1.0 mm	0.5-1.0 mm	100-200 µm (superficial)
Penetration Depth	5-10 mm (optimal), up to 2-3 cm	Unlimited	Unlimited	2-4 cm (high-freq)
Temporal Resolution	Seconds to minutes (real-time)	Minutes to hours	Seconds to minutes	Seconds (real-time)
Contrast Agent	NIR-II fluorophores (e.g., IRDye 800CW, CH1055, quantum dots)	Gadolinium-based (extracellular or intravascular)	Iodinated contrast	Microbubbles (contrast-enhanced) or none
Key Metric	Signal-to-Background Ratio (SBR) > 5	T1 relaxation time, enhancement kinetics	Hounsfield Units (HU)	Vessel diameter, flow velocity (Doppler)
Functional Data	Real-time drainage kinetics, valve function	Slow flow, interstitial pressure	Gross structural anomalies, lymph node size	Flow dynamics, tissue compressibility
Primary Limitation	Limited depth for high-resolution	Long acquisition, indirect lymph mapping	Radiation exposure, poor soft-tissue contrast	Operator-dependent, limited depth/resolution

3. Detailed Experimental Protocols

Protocol 3.1: Dynamic NIR-II Lymphatic Mapping in Rodent Models Objective: To visualize and quantify real-time lymphatic drainage and architecture. Materials: Anesthetized mouse/rat, NIR-II fluorescent agent (e.g., 50 µL of 100 µM IRDye 800CW PEG), intradermal syringe (33G), NIR-II fluorescence imaging system (e.g., InGaAs camera, 1064 nm laser excitation), heating pad. Procedure:

• Anesthetize the animal and position on a heated stage.
• Subcutaneously or intradermally inject the NIR-II agent into the paw pad or tail.
• Immediately initiate continuous NIR-II image acquisition (frame rate: 1-10 fps).
• Record the time to initial vessel appearance, propagation speed (µm/s), and drainage pathway to sentinel lymph nodes.
• Quantify signal intensity in regions of interest (ROI) over time to generate kinetic curves.
• Sacrifice animal, dissect, and perform ex vivo NIR-II imaging of excised lymphatic vessels and nodes for validation.

Protocol 3.2: High-Resolution MRI Lymphangiography for Lymphedema Objective: To non-invasively assess lymphatic vessel integrity and dermal backflow in lymphedema. Materials: Clinical 3T MRI, volume interpolated breath-hold examination (VIBE) sequence, gadolinium-based contrast agent (e.g., Gadobutrol), subcutaneous injection set. Procedure:

• Patient positioned prone in MRI scanner. Pre-contrast T1-weighted images are acquired of the limb.
• Inject 0.1 mL of gadolinium contrast intradermally into each web space of the hand/foot.
• Immediately initiate a dynamic 3D T1-weighted gradient-echo sequence (e.g., VIBE) over the limb and torso.
• Acquire sequential images every 5 minutes for 45-60 minutes post-injection.
• Analyze images for the presence, caliber, and course of enhancing lymphatic collectors. "Dermal backflow" appears as diffuse interstitial enhancement.
• Use maximum intensity projections (MIPs) for 3D visualization.

Protocol 3.3: Contrast-Enhanced CT for Lymph Node Staging Objective: To assess lymph node size, morphology, and metastatic involvement in oncology. Materials: Multi-detector CT scanner, iodinated contrast agent (e.g., Iohexol), power injector. Procedure:

• Patient receives intravenous iodinated contrast (100-150 mL) via power injector (rate: 2-3 mL/s).
• Scanning is performed in the portal venous phase (60-80 second delay).
• Images are reconstructed with axial, coronal, and sagittal slices (1-2 mm thickness).
• Lymph nodes are evaluated based on short-axis diameter (>10 mm in abdomen is often suspicious), morphology (round vs. oval), and enhancement patterns (heterogeneous vs. homogeneous).
• 3D reconstructions can map lymphatic drainage basins relative to tumors.

Protocol 3.4: High-Frequency Ultrasound for Superficial Lymphatic Assessment Objective: To measure lymphatic vessel diameter and flow in real-time. Materials: High-frequency ultrasound system (≥18 MHz linear transducer), ultrasound gel. Procedure:

• Apply ample gel to the skin surface over the region of interest (e.g., limb).
• Using B-mode, identify anechoic, tubular structures adjacent to veins and arteries.
• Switch to color or power Doppler mode with low velocity scale to detect slow lymph flow.
• Use pulsed-wave Doppler to obtain spectral waveforms and measure flow velocity.
• Switch back to B-mode to measure the inner diameter of the vessel in transverse view.
• Document dynamic changes with limb movement or manual compression.

4. Visualization: Pathways and Workflows

Title: Imaging Modality Decision Workflow for Lymphatic Research

Title: Integrated Preclinical Lymphatic Imaging Protocol

5. The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Research Reagents and Materials

Item	Function/Application	Example Product/Category
NIR-II Fluorophores	Provides high SBR for deep-tissue, real-time lymphatic mapping.	IRDye 800CW, CH-1055, PbS/CdS Quantum Dots, LICOR agents.
Gadolinium-Based MRI Contrast	Shortens T1 relaxation time, enabling visualization of lymphatic vessels on MRI.	Gadobutrol (Gadovist), Gadofosveset (Ablavar - blood pool agent).
Iodinated CT Contrast	Increases X-ray attenuation, outlining lymphatic vessels and nodes on CT.	Iohexol (Omnipaque), Ioversol (Optiray).
Ultrasound Microbubbles	Acoustic contrast agents for enhancing Doppler signals from lymphatic flow.	Phospholipid-shelled microspheres (e.g., Definity, SonoVue).
Lymphatic Tracers (Clinical)	For direct lymphography (oil-based) or sentinel node biopsy.	Patent Blue V, Isosulfan Blue, Indocyanine Green (ICG, NIR-I).
Intradermal/SubQ Injection Needles	Precise delivery of contrast agents into the interstitial space or dermal layer.	30-33G insulin syringes.
Image Co-registration Software	Fuses multi-modal datasets (NIR-II + MRI/CT) for correlative analysis.	AMIRA, 3D Slicer, MATLAB with advanced toolboxes.
In Vivo Imaging Systems	Hardware for acquiring NIR-II, MRI, CT, or high-resolution US data.	InGaAs NIR-II cameras, preclinical 7T/9.4T MRI, micro-CT, Vevo US.

Within the thesis on NIR-II imaging for lymphatic mapping, validation is paramount. In vivo NIR-II imaging provides dynamic, deep-tissue visualization of lymphatic architecture and function using targeted fluorophores. However, to confirm the specificity of probe localization, assess cellular-level pathology, and translate findings into diagnostic criteria, correlation with gold-standard histology is essential. This protocol details a rigorous workflow for processing tissues from NIR-II-imaged subjects (typically murine models) to enable direct spatial correlation between macroscopic fluorescence signals and microscopic histopathological features.

Key Quantitative Data from Recent Studies

Table 1: Representative NIR-II Agent Performance and Histological Correlation Metrics

NIR-II Probe / Target	Peak Emission (nm)	Lymphatic Model (Murine)	Key Histological Correlation Metric	Reported Correlation Coefficient (R²) / Concordance	Reference (Example)
CH-4T-based nanoparticle (Lyve-1 mAb)	~1050	Popliteal & iliac lymph nodes	% Area of Probe Co-localization with Lyve-1+ vessels	R² = 0.91 (Signal vs. Lyve-1+ area)	Zhang et al., 2022
Lyp-1 peptide conjugated IRDye 800CW	~800	Tumor-draining lymphatics	Tumor cell clusters in LN sections vs. NIR-II signal intensity	95% Concordance for metastasis detection	Liu et al., 2023
FDA-approved ICG	~1000-1100 (NIR-II tail)	Hindlimb lymphatic drainage	Functional lymphatic vessel count (Podoplanin+ )	R² = 0.87 (Drainage rate vs. vessel density)	Smith et al., 2023
A1094-loaded PEG-PLA nanoparticle (passive targeting)	1094	Sentinel lymph node	Macrophage infiltration (F4/80+ cells) in LN	R² = 0.78 (Signal intensity vs. cell count)	Chen et al., 2024

Detailed Experimental Protocol

Protocol 1: Integrated Workflow for NIR-II Imaging and Ex Vivo Histological Validation

Objective: To excise, process, and analyze tissues following in vivo NIR-II imaging to validate fluorescent findings with immunohistochemistry (IHC).

Materials (Scientist's Toolkit):

• NIR-II Imaging System: e.g., Custom or commercial setup (InGaAs camera, 808 nm/980 nm laser). Function: Non-invasive, real-time lymphatic mapping.
• Optimal Cutting Temperature (OCT) Compound: Function: Embedding medium for cryosectioning; preserves fluorescence and antigenicity.
• Cryostat: Function: Produces thin (5-10 µm) tissue sections for microscopy.
• Primary Antibodies (Species-specific): Anti-Lyve-1 (lymphatic endothelial cells), Anti-Podoplanin (lymphatic endothelial cells), Anti-CD31 (pan-endothelial), Anti-F4/80 (macrophages). Function: Bind specific antigens for IHC staining.
• Fluorophore-conjugated Secondary Antibodies: e.g., Alexa Fluor 488, Cy3. Function: Bind primary antibodies, providing visible fluorescence distinct from NIR-II channel.
• DAPI (4',6-diamidino-2-phenylindole): *Function: Nuclear counterstain.
• Epifluorescence/Confocal Microscope with NIR-capable detector: Function: Visualizes both NIR-II probe and IHC stains on the same section.
• Image Co-registration Software: e.g., ImageJ/Fiji with plugin, or commercial solutions. Function: Aligns and overlays NIR-II and histology images.

Procedure:

• In Vivo NIR-II Imaging: Anesthetize the animal. Administer the NIR-II probe (e.g., IV, intradermal). Acquire dynamic or static NIR-II images of the lymphatic region of interest (e.g., limb, tumor drainage). Document signal intensity and spatial distribution.
• Tissue Harvest & Fixation: Euthanize the animal at the prescribed endpoint. Surgically excise the lymph nodes or lymphatic tissues of interest. For fluorescence preservation, place tissue in 4% paraformaldehyde (PFA) for 4-6 hours at 4°C. Do not over-fix.
• Cryopreservation & Embedding: Rinse tissue in PBS, then incubate in a sucrose gradient (10%, 20%, 30% in PBS) until tissue sinks. Embed tissue in OCT compound in a cryomold and rapidly freeze on dry ice or in liquid nitrogen-chilled isopentane. Store at -80°C.
• Sectioning: Cut 5-10 µm thick sections using a cryostat. Mount sections on charged glass slides. Store at -80°C until staining.
• Immunofluorescence Staining: a. Thaw slides, rehydrate in PBS for 10 min. b. Draw a hydrophobic barrier around the tissue. Apply blocking buffer (5% normal serum, 1% BSA, 0.1% Triton X-100 in PBS) for 1 hour at RT. c. Incubate with primary antibody diluted in blocking buffer overnight at 4°C. d. Wash 3x with PBS-T (0.05% Tween-20). e. Incubate with fluorophore-conjugated secondary antibody (e.g., AF488) for 1 hour at RT, protected from light. f. Wash 3x with PBS-T. Apply DAPI (1 µg/mL) for 5 min. Wash and mount with anti-fade mounting medium.
• Multispectral Microscopy: First, image the section using the microscope's NIR-sensitive detector (or a separate NIR-II scanner) to capture the ex vivo distribution of the NIR-II probe. Then, using appropriate filter sets, capture images of the IHC signal (e.g., AF488) and DAPI.
• Image Analysis & Correlation: a. Using co-registration software, align the NIR-II image with the IHC fluorescence image using tissue landmarks. b. Quantify the NIR-II signal intensity within regions defined by positive IHC staining (e.g., Lyve-1+ areas). c. Perform statistical correlation (e.g., Pearson's coefficient) between in vivo NIR-II intensity, ex vivo NIR-II section intensity, and IHC-derived metrics (stained area, cell count).

Protocol 2: H&E Staining for Morphological Correlation

Objective: To provide essential morphological context for NIR-II findings, identifying metastases, immune cell aggregates, or tissue remodeling.

Procedure:

• Following sectioning (Step 4 above), air-dry slides and fix in pre-chilled acetone or formalin for 5-10 minutes.
• Perform standard H&E staining: Hematoxylin for 5-8 min, rinse, differentiate, blue. Eosin for 1-3 min.
• Dehydrate through graded alcohols, clear in xylene, and mount with permanent mounting medium.
• Digitize slides using a brightfield scanner. Annotate regions of interest (e.g., metastatic foci, germinal centers) and map these coordinates back to the NIR-II image for correlation.

Visualizations

Title: NIR-II to Histology Validation Workflow

Title: Coregistration Logic for NIR-II and IHC Data

Application Notes

Thesis Context: Within the advancement of NIR-II (1000-1700 nm) imaging for lymphatic system mapping, precise quantification of the modality's advantages over traditional NIR-I (700-900 nm) and visible light imaging is critical for validating its diagnostic and research utility. These metrics underpin its adoption in oncology, immunology, and drug development for tracking lymphatic metastasis, immune cell trafficking, and therapeutic biodistribution.

Quantitative Performance Metrics

The superiority of NIR-II imaging is quantified across three primary axes, as consolidated from recent literature.

Table 1: Comparative Metrics of NIR-I vs. NIR-II Imaging for In Vivo Lymphatic Mapping

Metric	NIR-I Region (e.g., 800 nm)	NIR-II Region (e.g., 1500 nm)	Quantitative Advantage & Implication
Tissue Scattering	High (Scales as λ^-α)	Low	~5-10x reduction in scattering enables clearer anatomical definition of lymphatic vessels and nodes.
Autofluorescence	High from tissues	Significantly Suppressed	>90% reduction in background, enabling detection of deeper or fainter lymphatic signals.
Penetration Depth	Limited (~1-3 mm)	Enhanced	Up to ~8-10 mm achievable, facilitating imaging of deep lymphatic basins (e.g., abdominal, thoracic).
Spatial Resolution	Degrades with depth	Maintained with depth	Up to ~25 µm at >3mm depth, allowing visualization of fine lymphatic architecture.
Temporal Resolution (Speed)	Often limited by SNR	High SNR enables faster acquisition	Permits frame rates >50 fps for tracking rapid lymphatic flow dynamics.
Signal-to-Background Ratio (SBR)	Moderate (~2-5)	High	SBR can exceed >10-50, critical for differentiating sentinel lymph nodes from surrounding fat.

Table 2: Key Metrics for Longitudinal Monitoring of Lymphatic Function

Metric	Measurement Protocol (NIR-II)	Diagnostic/Research Relevance
Lymphatic Flow Velocity	Time-series imaging of contrast agent front; pixel-wise correlation analysis.	Quantifies lymphedema progression or therapeutic response.
Node Drainage Kinetics	Time-to-peak (TTP) and half-clearance time (T₁/₂) of contrast intensity within node.	Assesses nodal function and metastatic obstruction.
Vessel Permeability Index	Extravasation rate of NIR-II agents from lymphatic capillaries post-injection.	Evaluates inflammatory conditions or tumor microenvironment.
Tumor Afferent/Efferent Mapping	Spatiotemporal tracking of tracer from tumor periphery to sentinel nodes.	Critical for staging cancer metastasis.

Detailed Experimental Protocols

Protocol 1: High-Speed, High-Sensitivity Mapping of Sentinel Lymph Nodes (SLN)

• Objective: Identify and characterize the first draining lymph node(s) from a tumor site with maximal SBR.
• Reagents: NIR-II fluorophore (e.g., IRDye 1500 conjugated to bovine serum albumin or a clinically approved agent like indocyanine green (ICG) for its NIR-II tail emission); sterile PBS; anesthesia.
• Imaging System: NIR-II fluorescence imaging system with a 1064 nm excitation laser, InGaAs camera, 1300 nm long-pass emission filter.
• Procedure:
  • Anesthetize the animal (e.g., mouse bearing a subcutaneous tumor).
  • Prepare a 100 µM solution of the NIR-II agent in PBS.
  • Inject 10-20 µL of the agent intradermally at the tumor periphery using a 31-gauge insulin syringe.
  • Initiate rapid time-lapse imaging (1-5 frames per second) over the primary tumor and adjacent nodal basin.
  • Speed Metric: Record the time from injection to first visual signal in the SLN (often < 30 seconds with NIR-II).
  • Sensitivity Metric: After 5-10 minutes, capture a high-SNR static image. Quantify the SBR as (SignalNode - BackgroundRegion) / (StdDev_Background).
  • Longitudinal Protocol: Repeat at days 0, 3, 7 post-therapeutic intervention (e.g., radiotherapy, immunotherapy) to monitor changes in drainage kinetics and nodal architecture.

Protocol 2: Quantitative Longitudinal Monitoring of Lymphatic Flow in a Lymphedema Model

• Objective: Serially quantify changes in lymphatic flow velocity post-surgical intervention.
• Reagents: NIR-II lymphatic tracer (e.g., PEGylated carbon nanotubes or Ag₂S quantum dots with peak emission >1200 nm); anesthesia; surgical tools.
• Imaging System: As above, with capacity for high-frame-rate video recording.
• Procedure:
  • Establish a murine tail or hind limb lymphedema model via surgical ligation of lymphatic vessels.
  • At designated timepoints (pre-ligation, day 1, 3, 7, 14 post-ligation), anesthetize the animal.
  • Inject 5 µL of NIR-II tracer intradermally at a consistent distal site (e.g., tail tip or footpad).
  • Immediately record a >50 fps video for 60 seconds along the lymphatic vessel pathway.
  • Flow Analysis: Use particle image velocimetry (PIV) or kymograph analysis (using ImageJ) on the video sequence. Calculate flow velocity (µm/s) by tracking the leading edge of the fluorescent bolus over time.
  • Data Table: Plot mean flow velocity versus time post-ligation to objectively document dysfunction and potential recovery.

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for NIR-II Lymphatic Imaging Research

Item	Function & Rationale
NIR-II Fluorophores (Ag₂S QDs, SWCNTs, Organic Dyes)	Emit light in the NIR-II window, offering deep penetration and low background for vessel mapping.
ICG (for NIR-II Tail Imaging)	FDA-approved dye; its emission >1000 nm can be captured by sensitive InGaAs cameras for clinical translation studies.
PEGylation Reagents (e.g., mPEG-NHS)	Conjugation to fluorophores improves hydrophilicity, biocompatibility, and lymphatic drainage kinetics.
InGaAs NIR Camera (Cooled)	Essential detector for NIR-II light, with quantum efficiency >80% in 1000-1600 nm range.
1064 nm Laser Source	Common excitation wavelength that minimizes tissue autofluorescence and lies within the "optical transparency" window.
Long-pass Emission Filters (>1300 nm)	Blocks excitation laser and shorter-wavelength autofluorescence, isolating the pure NIR-II signal.
Micro-injection Syringes (31G)	Enables precise intradermal administration of tracer for reproducible lymphatic uptake.
Rodent Lymphedema Model Kits	Standardized surgical tools for creating reproducible lymphatic dysfunction models.

Visualizations

Workflow for NIR-II Lymphatic Mapping & Metric Quantification

Lymphatic Drainage Pathway & Key NIR-II Monitoring Points

Current Limitations and Technical Boundaries of NIR-II for Clinical Translation

Quantitative Limitations of Current NIR-II Technologies

The clinical translation of NIR-II imaging, while promising for applications like lymphatic system mapping, faces several quantifiable constraints.

Table 1: Key Technical Limitations and Their Quantitative Impact

Limitation Category	Specific Parameter	Current State-of-the-Art (Approx.)	Clinical Requirement (Estimated)
Agent Brightness & Stability	Quantum Yield (QY) in aqueous buffer	0.5-5% for many inorganic probes (e.g., Ag₂S)	>20% for low-dose administration
	Circulation Half-life (t½) of small-molecule dyes	Minutes to a few hours	Hours to days for comprehensive mapping
	Photostability (50% bleach time)	Variable; organic dyes can bleach rapidly	High stability for prolonged procedures
Imaging System Performance	Temporal Resolution for dynamic imaging	~5-30 frames per second (fps) at high SNR	>30 fps for capturing lymphatic flow
	Practical Depth Penetration in tissue	~5-8 mm for high-resolution mapping	>20 mm for deep-tissue lymph node assessment
	Cost of a dedicated NIR-II imaging system	$100,000 - $300,000+	Significant barrier to clinical adoption
Agent Biocompatibility	Hydrodynamic Diameter for renal clearance	<6 nm for efficient clearance	<10 nm ideal to avoid long-term accumulation
	Metal ion leakage (for QDs, SWCNTs)	Varies; a persistent concern	Must be undetectable or negligible

Detailed Experimental Protocols

Protocol 2.1: In Vivo Assessment of Novel NIR-II Dye for Lymphatic Mapping Aim: To evaluate the pharmacokinetics and lymphatic vessel imaging capability of a new organic NIR-II dye (e.g., CH-4T derivative). Materials: Animal model (e.g., nude mouse), NIR-II dye solution (100 µM in saline with 5% DMSO), heating pad, depilatory cream, small animal NIR-II imaging system (e.g., InGaAs camera, 1064 nm laser excitation, 1300 nm long-pass filter), 29G insulin syringe, isoflurane anesthesia system. Procedure:

• Animal Preparation: Anesthetize the mouse with 2% isoflurane. Remove hair from the hind limb and lower abdomen using depilatory cream. Place the animal prone on a heated stage.
• Dye Administration: Subcutaneously inject 20 µL of dye solution into the footpad of the hind limb using the insulin syringe.
• Image Acquisition: Immediately begin time-series imaging. Acquire images every 10 seconds for the first 5 minutes, then every minute for 60 minutes. Use constant laser power and camera settings.
• Data Analysis: Use ROI analysis to plot signal intensity in the popliteal lymph node over time. Calculate metrics: time-to-first-detect (TFD), time-to-peak (TTP), and signal-to-background ratio (SBR) at peak.
• Clearance Assessment: Image the same animal at 24h and 48h post-injection to assess dye clearance from the lymphatic organs.

Protocol 2.2: Benchmarking Photostability of NIR-II Probes Aim: To quantitatively compare the photobleaching resistance of candidate probes under clinically relevant irradiation. Materials: NIR-II probes in solution (e.g., PbS quantum dots, rare-earth nanoparticles, organic dye), quartz cuvette, NIR spectrometer or imaging system, calibrated 808 nm or 980 nm laser with adjustable power. Procedure:

• Sample Preparation: Dilute each probe to an optical density of ~0.1 at the excitation wavelength in a standard buffer (e.g., PBS).
• Irradiation Setup: Place the cuvette in the imaging/spectroscopy setup. Focus the laser beam to uniformly illuminate the sample volume. Set laser power to 100 mW/cm² (simulating clinical fluence).
• Continuous Monitoring: Acquire the NIR-II fluorescence signal (spectrum or intensity) continuously or at 10-second intervals.
• Analysis: Plot normalized fluorescence intensity versus time. Calculate the half-life (t½) of photobleaching, defined as the time for the signal to decay to 50% of its initial value.

Visualization Diagrams

Diagram 1: NIR-II Clinical Translation Pathway

Diagram 2: Key Signal Attenuation Factors in Tissue

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for NIR-II Lymphatic Research

Item	Function & Relevance	Example/Note
Organic NIR-II Fluorophores (e.g., CH-4T, FT-26)	High brightness small-molecule dyes for rapid lymphatic uptake and clearance. Essential for dynamic imaging.	Often require formulation with surfactants (e.g., F127) for in vivo use.
Bioconjugation Kits (NHS, Maleimide)	For attaching targeting ligands (e.g., LyP-1 peptide) to NIR-II probes to target specific lymphatic endothelial cells or tumors.	Critical for moving from passive to active targeting.
Renal Filtration Marker (e.g., IRDye 680RD)	Co-inject to confirm probe size is below renal cutoff, a key safety parameter for clinical translation.	Used in clearance validation experiments.
Matrigel / Growth Factor Reduced	For creating in vitro 3D lymphangiogenesis models to test probe extravasation and binding.	Simulates the extracellular matrix.
Lymphatic Endothelial Cell (LEC) Media	Specialized culture media for maintaining primary LECs in vitro for cytotoxicity and uptake studies.	Required for standardized biocompatibility testing.
Indocyanine Green (ICG)	The only FDA-approved NIR-I dye; serves as the critical benchmark for performance and safety comparison.	Gold standard for comparative imaging studies.
Commercial NIR-II Imaging System	Integrated systems (e.g., from NIRx, SurgVision) provide standardized hardware/software for reproducible data.	Reduces technical variability between labs; necessary for preclinical validation.

Conclusion

NIR-II fluorescence imaging represents a paradigm shift in lymphatic system visualization, offering unparalleled capabilities for high-resolution, deep-tissue mapping and functional diagnosis in pre-clinical research. By leveraging the superior optical properties of the NIR-II window, researchers can overcome longstanding limitations of traditional imaging, enabling precise study of lymphatic architecture, drainage dynamics, and disease progression. The synthesis of advanced contrast agents with optimized imaging protocols provides a powerful toolkit for investigating lymphedema, cancer metastasis, and immune responses. While challenges in agent clinical translation and instrumentation cost remain, the continued evolution of NIR-II technology promises to accelerate drug development targeting lymphatic pathways and pave the way for future minimally invasive diagnostic procedures. The integration of NIR-II imaging with other modalities and the development of targeted, clinically approved agents are critical next steps for realizing its full potential in biomedical and clinical research.